Vaccines and Global Health: The Week in Review
07 January 2023 :: Issue 685
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

Editor’s Note:
Vaccines and Global Health: The Week in Review resumes publication with today’s edition following an end-of-year, holidays break.
Meeting of the Strategic Advisory Group of Experts on Immunization, October 2022: conclusions and recommendations

Weekly epidemiological record, 6 January 2023
PDF: https://apps.who.int/iris/rest/bitstreams/1487149/retrieve

Overview
The Strategic Advisory Group of Experts (SAGE) on Immunization held a meeting on 3-6 October 2022. This report summarizes the discussions, conclusions and recommendations. It covers the following items:
- Global Reports
- Immunization Agenda 2030 and Regional reports
- Monkeypox
- RSV
- COVID-19 vaccines
- Polio vaccination
- Ebola (Sudan ebolavirus outbreak update)

SAGE conclusions and recommendations
SAGE commended the IA2030 progress with country ownership and endorsed the following recommendations presented by the IA2030 secretariat. These provide a set of priorities around which global, regional, and national stakeholders can align to drive actions in 2022–2023.

1. Urgent actions needed to address the backsliding during the COVID-19 pandemic and promote catch-up vaccination.
   a. Support restoration and recovery: identify the national, regional, and global actions and technical support needed to strengthen national essential immunization services and surveillance systems as part of integrated primary health care (PHC), systems strengthening and pandemic preparedness.
   b. Leverage COVID-19 lessons: identify and share successful approaches to mainstreaming COVID-19 vaccination into the delivery of other essential immunization services by establishing or strengthening platforms to deliver PHC interventions across the life course.
   c. Accelerate integrated catch-up: design and implement catch-up campaigns that are focused on equity and tailored to local contexts, and that encompass children beyond 2 years of age, using root cause analyses to shape the design; establish policies that facilitate vaccination beyond the scheduled target age for those missing vaccination.

2. Medium- and long-term actions to strengthen immunization programmes as a core component of resilient and equitable PHC and pandemic preparedness and response.
   d. Enhance the health workforce: map out current and anticipated health workforce needs; identify and address the factors affecting health worker retention; use new learning and performance management approaches to enhance health worker capacity.
e. **Prioritize health:** ensure prioritization of PHC and immunization in government budgets; promote the efficient use of resources; identify strategies to mobilize additional financing for immunization and health systems.

f. **Promote equity:** strengthen systematic monitoring of equity to underpin actions to reduce socioeconomic and geographical disparities in vaccination coverage within countries, including strengthening of cross-sectoral subnational accountability mechanisms.

g. **Strengthen demand generation:** promote the use of globally validated tools to assess behavioural and social drivers of vaccination at all levels of immunization programmes; use the data to understand the reasons for low uptake and guide continued improvement of strategies to close gaps in coverage and equity.

3. **Actions needed to address new vaccine introduction**

h. **Accelerate new vaccine introductions:** understand and overcome barriers to the introduction of WHO-recommended vaccines; prioritize their introduction according to the country context.

i. **Advance vaccination in adolescence:** identify the most effective ways to strengthen platforms for vaccination of older children and adolescents, particularly HPV vaccination.

4. **Actions needed to accelerate vaccine development**

j. **Invest in vaccine research:** strengthen the global research environment for new vaccine development and implementation, including increased investment in new vaccine research and development for priority pathogens, leveraging COVID-19-driven technological innovations.

k. **Support diversification of global manufacturing capacity** and strengthen the capacity of national and global regulatory authorities.

5. **Actions needed to enhance coordination and promote global monitoring, evaluation and accountability cycles for continuous quality improvement**

l. **Enhance knowledge sharing:** create a “knowledge-sharing hub” where partners can share their analyses, intelligence and other evidence relevant to achieving IA2030 objectives.

m. **Achieve change:** establish M&E cycles at global, regional and national levels with a feedback loop to facilitate a common understanding of the issues and promote concerted actions.

---

**Featured Journal Content**

*Vaccine: X*

Volume 13, April 2023, 100256

**Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021–2030**

Salin Sriudomporn, et al.

*Under a Creative Commons license Open access*

**Highlights**

:: Routine immunization costs account for majority of total costs for the next decade.
:: Resource mobilization and increasing investment are essential to achieve IA2030.
:: UMICs require the largest increase in investment to achieve IA2030 coverage.
:: Vaccine prices could drive the increase in the total resources required.

**Abstract**
Understanding the level of investment needed for the next decade is vital to achieve the goal of Immunization Agenda 2030 (IA2030). Through the immunization funder perspective, this study estimates both global and regional economic resources required to achieve IA2030 coverage among 194 WHO member countries from 2021 to 2030, against 14 pathogens: Hepatitis B (Hep B), Haemophilus influenzae type b (Hib), Human papillomavirus (HPV), Japanese encephalitis (JE), Measles, Meningitis A (Men A), Streptococcus pneumoniae, Rotavirus, Rubella, Yellow Fever (YF), Diphtheria, Tetanus, Pertussis, and Tuberculosis.

The total cost of immunization program, routine vaccine, routine delivery, and non-routine costs (SIA and stockpile) were estimated using WHO coverage forecast for IA2030. Incremental costs of achieving IA2030 for all vaccines and cost per immunized child were also assessed. All costs were calculated for each income and regional level, as well as global level. Scenario analysis and sensitivity analysis were conducted to account for uncertainty in future vaccine pricing and delivery costs.

The total cost of immunization programs is $269.8 billion (95% confidence interval: $247.1 - $311.8), of which $152.8 billion is considered as routine vaccine cost, $114.9 billion is routine delivery cost. Non-routine cost for LICs and LMICs totaled $2.1 billion. The incremental cost of achieving coverage goals after 2020 is $89.9 billion ($27.7-$110.1), with upper-middle income countries requiring the largest increase in investment (56.2% of incremental costs). The average immunization cost per child across all countries is $192.6. Scenario analysis using the minimum and maximum vaccines price for fully self-financing countries resulted in total costs ranging from $193.6 and $552.2 billion.

The immunization program cost among 194 WHO member countries is expected to increase during this decade. The strategy for resource mobilization and increasing investment from country governments and donors are essential to achieving IA2030 coverage and ensuring sustainable immunization programs.

---

Editor’s Note:
We commend to your reading the full, extended essay by Richard Hatchett available at the title link below. We provide an excerpt focused on equity.

CEPI CEO Dr Richard Hatchett reflects on 2022
21 Dec 2022
[Excerpt; Editor’s text bolding]

...As one of the people who conceived and then worked hard to bring COVAX to life, I am proud of the impact it has had. But as someone who is also deeply committed to the causes of justice and fairness, I am at the same time mindful of what the world might have achieved but did not.

We can now define that gap, and how many lives were lost in consequence, with some precision, as the MRC Centre for Global Infectious Disease Analysis (GIDA) at Imperial College has recently published an assessment of the global impact of COVID vaccination. [3] Overall, the authors of this assessment estimated that in the year after the first vaccines were authorized, the global immunization
A campaign had prevented just under 20 million excess deaths worldwide, including 7.4 million in COVAX AMC countries. These are astounding numbers. But the authors also estimated that while globally immunization had prevented 63% of potential total deaths (19.8 million of an estimated 31.4 million excess deaths in the absence of vaccine), in COVAX AMC countries only 41% of potential total deaths were averted (7.4 million of 17.9 million). Had the COVAX AMC countries had equal access to vaccine, hundreds of thousands or even millions of additional lives could have been saved.

To prevent such tragedies from recurring, we have to understand their root causes. At CEPI, we’ve reflected deeply on our experiences with COVAX and our observations of the global response. A key takeaway from the last three years is that the system and capabilities to respond that we had in 2020 were not configured to produce equity as a natural output of the system’s operation. The initial scarcity of vaccine was a huge problem; but so were the lack of financing mechanisms to enable large-scale, globally distributed production and the lack of healthcare capacity in many countries to deliver vaccines to high-risk populations. The majority of global manufacturing and almost all vaccine development capacity is located in the US, EU, India and China, and vaccine manufacturers located in these regions encountered irresistible pressure to serve these populations first. All of these factors stood in the way of vaccine equity. We would have needed to solve for all of them simultaneously to prevent the inequities that emerged.

The system was perfectly designed to achieve the results it achieved. If we don’t like the system’s output, we will need to reengineer it. And we will need to do so systematically.

Understanding equity as a systems problem is helpful for an organization like CEPI. Some of the factors contributing to inequity CEPI can tackle directly; some we can influence; and some we can only talk about. We can work to minimize scarcity by increasing the speed of vaccine development and production; and we can work with our technical and financial partners to expand vaccine manufacturing capacity in underserved regions, mitigating the problem of vaccine nationalism. While delivering vaccines is not part of CEPI’s remit, we can advocate for the establishment of adult vaccination programs to extend the benefits of routine vaccines to all segments of the population while building capacity to deliver countermeasures against future threats. We can participate in mechanisms like the Pandemic Fund to strengthen new financial mechanisms and instruments and ensure that they are fit for purpose, and we can work more closely with civil society partners to inform and empower grassroots activists. Applying a “systems equity” perspective to the lessons we have learned from COVID-19 has changed how we think about and organize our activities and commitments, and it has helped us to articulate more explicitly the rationale for actions we had previously pursued only intuitively. In the year to come, we will be talking a lot more about our new Equitable Access Framework and its implementation plan.

Collectively, we are making progress. New international institutions are being established that will sustain and increase this momentum. I’ve already mentioned the Pandemic Fund, which was championed by Indonesia during its G20 presidency and stands as one of its chief accomplishments. The fund is woefully undercapitalized, but it establishes, for the first time, a joint financing mechanism to support pandemic preparedness and response.[4] In December 2021, in only its second-ever special session, the World Health Assembly established an intergovernmental negotiating body to draft and negotiate a new convention (or so-called “Pandemic Treaty”) to strengthen pandemic prevention, preparedness and response. At the same time, a growing number of governments are establishing agencies dedicated to the development and production of medical
countermeasures. Wellcome has set up an international Secretariat for the G7 to track progress against the 100 Days Mission, and Japan has retained the 100 Days Mission, now expanded to include manufacturing, as a key priority for its 2023 G7 presidency.

All of this is for the good, and important, but institutional change is slow...

::::::

Featured Journal Content

JAMA
January 3, 2023, Vol 329, No. 1, Pages 5-104
https://jamanetwork.com/journals/jama/currentissue

Viewpoint

Urgent Need for Next-Generation COVID-19 Vaccines
Peter W. Marks, MD, PhD; Philip A. Gruppuso, MD; Eli Y. Adashi, MD, MS
free access has audio

Despite the availability of safe and effective vaccines, SARS-CoV-2 continues to circulate rampantly across the globe. Problems with vaccine access and hesitancy present throughout the pandemic are partially responsible. However, the seemingly ceaseless progression of increasingly transmissible variants, recently including BF.7 and BQ.1.1, presents a major challenge to medical interventions, particularly vaccines.

Attempting to address the continued genetic evolution of SARS-CoV-2, the US Food and Drug Administration authorized bivalent boosters (original plus BA.4/BA.5 Omicron variant) for the 2 available messenger RNA (mRNA) COVID-19 vaccines to address the waves of disease leading to hospitalization and death. These updated vaccines may also reduce the amount of symptomatic disease and associated health care use. However, introduction of these bivalent boosters likely only represents a temporizing measure until variants emerge that necessitate additional booster vaccination or modification of the current generation of vaccines.

The existing COVID-19 vaccines have had a profoundly positive effect during the pandemic, reducing both hospitalization and death. However, those at risk of severe outcomes from COVID-19, especially older individuals, have required booster vaccination even to maintain this level of protection. The need to repeatedly vaccinate at-risk populations, combined with the documented emergence of a new dominant SARS-CoV-2 variant approximately every 3 to 4 months, presents a public health dilemma.1

Continuing along the current path of the generation and administration of variant-specific vaccine boosters is inadequate as a long-term strategy for addressing COVID-19 in populations globally.

There is also a risk that eventually a variant will emerge that will escape the protection provided by the current generation of vaccines against severe disease. Experience with SARS-CoV-2 infection to date in older individuals indicates that higher antibody titers tend to correlate better with prevention of severe COVID-19. Therefore, older individuals may be at risk for becoming the initial group most susceptible to such novel variants that lack adequate antibody coverage. Serious consideration therefore needs to be given to the development of a distinctly improved generation of SARS-CoV-2 vaccines offering longer protection with greater scope.
Based on experience to date with COVID-19 and other vaccines, a variety of approaches to the development of new vaccines will need to be explored by academic and industrial researchers and sponsors, as well as government agencies. One potential model for approaching such development was used successfully at the beginning of the pandemic when Operation Warp Speed evaluated numerous global vaccine types and focused on advancing several promising candidates, knowing full well that most would ultimately not be found to meet the criteria set forth for a safe vaccine with adequate efficacy. Such focused effort, along with technical and financial resources, will likely be required to overcome the significant challenges intrinsic to efforts to develop a vaccine having the needed extent and duration of protection.

Developing the next generation of vaccines addressing SARS-CoV-2 will be demanding. This work will almost certainly require more than simply making incremental modifications on the current generation of vaccines. Although experience with the mRNA vaccine platforms has enabled authorization of updated versions of vaccines without large clinical trials, when more significant modifications are made to a vaccine, the clinical effects are often unexpected. Biological properties that may plausibly have beneficial effects often have unanticipated consequences. Therefore, unless correlates of protection that are strongly associated with duration of protection against COVID-19 can be identified, it is likely that rather than relying on immunobridging to infer vaccine effectiveness, large randomized clinical trials similar to the initial trials of the currently authorized or licensed vaccines for COVID-19 will be required to ascertain the effectiveness of these new vaccines.

Simply updating the existing vaccine constructs with new variant sequences or even making trivalent or quadrivalent vaccines covering several variants is not likely to provide the depth and breadth of protection needed to interrupt viral transmission during a prolonged period. It is also not at all clear from well-controlled clinical trials that administering existing vaccines by the intranasal route (as some countries have already even approved) will provide truly meaningful benefit over the existing generation of COVID-19 vaccines. Such limitations were recently illustrated by the disappointing results with a viral-vectored vaccine administered intranasally in an early-phase clinical trial.

However, the situation is far from hopeless because there are other approaches to future COVID-19 vaccine development currently under investigation, including potentially effective means of achieving improved mucosal immunity with or without intranasal administration. These approaches might include, among many other methods, targeting S protein viral sequences that are immutable, immunogenic, and accessible to neutralizing antibodies; including other targets from the virus such as portions of the membrane, envelope, or nucleocapsid proteins; targeting conserved or occluded (structurally hidden) epitopes using nanoparticles of randomly arrayed receptor binding domains; and developing vaccines based on T-cell receptor constructs that specifically recognize the SARS-CoV-2 RNA-dependent RNA polymerase.

So what would define success for these new vaccines? To truly represent a significant advance in this area, the protection provided by vaccination would need to apply across a wide range of potential variants that might emerge. In terms of the actual level of effectiveness, the minimum expectations for such a vaccine might be adopted from the criteria used in the search for an acceptable “universal” influenza vaccine. The National Institute of Allergy and Infectious Diseases defines the threshold for influenza vaccine as at least 75% effectiveness in preventing influenza-like illness, achieving durable protection that lasts at least 1 year, and suitability for use in all age groups. Aiming even further, the vaccines would ideally not only protect against hospitalization, death, and symptomatic disease leading
to increased health care use but would also reduce viral transmission. Even using the criterion for success of a moderate 40% to 60% reduction in transmission is predicted to have a notable positive impact on outbreak control.7

The continued adverse effects of SARS-CoV-2 on individuals and populations necessitate the urgent development of the next generation of vaccines. The adverse effects wrought by SARS-CoV-2 extend far beyond the acute complications of COVID-19 to post–COVID-19 conditions. Achieving success in developing improved vaccines will obviously be a major challenge, given all that we have learned to date about this virus, the human response to infection, and the immune correlates of protection after vaccination. However, an attempt to produce vaccines that lead to broad long-lasting immunity is clearly needed. Additionally, although reducing viral transmission is a difficult objective, the potential benefits to global public health are profound enough to merit acceptance of the challenge. Particularly, if immunity that reduced disease transmission could be elicited by a relatively inexpensive, easily administered vaccine stored at room temperature, a much greater fraction of the world’s population could be readily immunized, perhaps slowing the emergence of troubling variants.

What we learn as we address the challenges posed by SARS-CoV-2 and COVID-19 about virology and immunology, along with the accompanying advances in technology and manufacturing that will come from developing the next generation of vaccines, may broadly benefit public health during our current era of constantly emerging and reemerging infectious diseases.

Editor’s Note:

We celebrate the release of the report below addressing a critically important “gap” [among too many others] in responsible pandemic response. We do not celebrate the gap of a year-plus between the Summit event itself [06 December 2021] and the release of this document disseminating its findings.

Bridging the gap between ethics and decision-making in pandemics: report of the WHO Pandemic Ethics and Policy Summit, 6 December 2021

22 December 2022

Overview

This document presents a summary report of the WHO Pandemic Ethics and Policy Summit organized by the World Health Organization (WHO) on Monday, 6 December 2021.

Executive summary [Editor’s text bolding and some formatting for readability]

The COVID-19 pandemic has raised profound ethical challenges on an unprecedented global scale. These challenges include how to allocate scarce resources (especially vaccines and therapeutics), both within and between countries, whether and when to mandate vaccines and/or masks, whether and how to conduct public health surveillance, whether to issue vaccine passports, and how to address stark international and intranational inequities. In addition, there have been ethical concerns about the conduct of COVID-19 research, such as the appropriateness of challenge studies.

Simultaneously, and in an unprecedented manner, ethical values like equity, fairness, solidarity, and trust have figured prominently in global discussions. But the question remains: how much progress, if any, have we made in achieving these values and in progressing towards global health justice? Much has been said about the importance of
evidence-informed decision-making, but what have we achieved in terms of ‘ethics-informed decision-making’?

The WHO Pandemic Ethics and Policy Summit, organized by the WHO Heath Ethics and Governance Unit in collaboration with WHO’s Working Group on Ethics and COVID-19 and ACT-Accelerator Ethics and Governance Working Group, provided a forum to discuss the translation of ethics into policy-making during the COVID-19 pandemic, examine where we have succeeded and failed, and ask what major challenges and steps remain to improve ethics-informed policy-making for pandemic preparedness and response.

What emerged is a clear message that while every decision over the course of the pandemic has indeed had ethical dimensions, not every decision has meaningfully engaged with ethics.

This has occurred for several reasons:
:: First, policymakers were not always aware that certain decision were inherently of an ethical nature.
:: In addition, ethicists have not always been in a position to inform decisions.
:: Third, the urgency with which decisions have had to be made was perceived as antithetical to careful consideration of ethical considerations.
:: Finally, unequal power of decision-makers has in many cases undermined the ethical path forward. Because solidarity, equity, transparency, and global justice are ethical values, there is a likelihood these values will be ignored, misapplied, or distorted by powerful interests if policy-makers do not meaningfully incorporate ethics into policy-making.

If equity, solidarity, maximizing benefits, global justice and other ethical values are to serve as key commitments in pandemic response, ethics cannot be an afterthought. Ethics must be a starting point. To live our stated values, ethics in policy-making is essential.

For ethics to be meaningfully incorporated into policy-making, it is imperative that ethicists be included in the policy-making process. Ethicists are trained to appraise and inform policy-making in a systematic way by (i) raising awareness of the important ethical dimensions of a policy or issue under consideration, (ii) identifying and clarifying different policy options, (iii) mapping out ethical arguments in favour of and against different policy options, and (iv) anticipating the ethical implications of particular policy options. Ethicists are also positioned to ask uncomfortable questions. Accordingly, to be of value, ethicists must be meaningfully embedded in policy-making such that they are fully aware of the different factors that should influence decision-making, anticipate challenges and counterarguments, and have direct conversations with people who make decisions. And they must be able to provide practical advice in a timely manner. Ethicists can also work to enhance the moral quality of decision-making processes, e.g., by appealing for transparency, outlining frameworks of accountability, advocating for the inclusion of perspectives from the least advantaged, challenging governance arrangements that privilege the wealthy at the expense of the poor, and articulating how justifications for policies should be communicated to the public.

Many examples were raised during the Summit of the successful inclusion of ethicists at policy tables locally, regionally, nationally, and internationally. In some cases, the COVID-19 pandemic represented the first time ethicists were incorporated into policy-making structures. But this was not the case everywhere. While many barriers exist for the meaningful incorporation of ethics into policy-making, this is predicated on local ethics capacity. Consequently, ethics capacity building should be
embedded in all forms of scientific, health, and policy education. Whether or not ethicists have a role in policy-making, they should play a role in shaping public discourse to ensure ethics becomes part of larger societal discussions around the pandemic and pandemic response.

Where the inclusion of an ethicist in policy-making is not feasible or possible, tools such as ethics checklists or guidebooks may be used to ‘inject’ the explicit consideration of ethics into the policy-making process. For instance, when considering allocation of resources, a checklist might assess whether the policy was fulfilling the values of maximizing benefits, providing equal concern to all, and mitigating, or at least not worsening, disadvantage. A checklist like this provides a systematic way for ethical issues and values to be considered. This is crucial especially given power dynamics that may otherwise eschew or attenuate the role of ethical considerations in the policy-making process. Yet, checklists or guidebooks represent only a partial solution; such tools should prompt ethical reasoning and deliberation to understand the salience of ethical considerations and to arrive at the most ethically defensible decision.

To improve the role of ethics in policy-making, mutual learning must occur between ethicists and policy-makers. Robust ethical guidance exists for many issues expected to be experienced during a pandemic. Yet, ethicists must work harder to translate complex, nuanced ideas in a manner that is practicable for policy-makers and articulate the practical applications of key ethical values and commitments, like equity and solidarity. Also required are tools to measure and evaluate the achievement of such values and commitments. There will be no one-size-fits-all approach to the meaningful integration of ethics in policy-making. Like efforts to understand and improve ‘evidence to policy’, further research exploring effective ‘ethics to policy’ models that includes interdisciplinary perspectives from ethics, policy, political science, and the health sciences will be integral.

The COVID-19 pandemic has been marked by moral failures. We cannot expect to correct these moral failures without improving the ways in which ethical values and commitments are incorporated into the policy-making process. It is hoped that this Summit serves as a catalyst for much-needed empirical, theoretical, and normative work to better understand and improve ‘ethics to policy’ in pandemic prevention, preparedness, and response.

COVID – China Focus

WHO Director-General’s opening remarks at information session for Member States – 5 January 2023

5 January 2023
Honourable Ministers, Excellencies, dear colleagues and friends, Happy New Year and good morning, good afternoon and good evening to all Member States, and thank you all for joining us on our first information session of the year.

Now into the fourth year of the COVID-19 pandemic, the world is in a much better place than it was several years ago, due to clinical care management, vaccines and treatments.
For most of last year, COVID-19 was on the decline. Vaccination increased across the world, and there was sustained progress in many lower- and middle-income countries. New lifesaving antivirals were identified, which helped cut mortality.

On Christmas Day, WHO announced that the antivirals Nirmatrelvir and Ritonavir were prequalified for production by an Indian manufacturer. This is the first generic version of an antiviral to get WHO approval and should lead to increased production and access; particularly in lower- and middle-income countries.

But the threat of COVID-19 persists. Major inequalities in access to testing, treatment and vaccination continue. Every week, approximately ten thousand people die of COVID-19. The true toll is likely much higher. And the current COVID-19 epidemiological picture is troubling.

There is intense transmission and pressure on health systems particularly in temperate regions of the northern hemisphere, and a recombinant sub-variant spreading quickly. XBB.1.5 is the recombinant of two BA.2 sub-lineages. It was originally identified in October 2022, has now been detected in 29 countries and appears to be growing quickly in some geographies. WHO is following closely, assessing, and will report on the risk to Member States accordingly.

China is experiencing very high transmission at the moment and last week WHO held a series of high-level meetings with our counterparts to discuss the surge in cases and hospitalisations.

This week, WHO’s Technical Advisory Group on SARS-CoV-2 Virus Evolution, which also met with Chinese experts, released a statement that noted, “the critical need for and importance of additional analysis as well as sharing of sequence data to understand the evolution of SARS-CoV-2 and emergence of concerning mutations or variants.”

WHO is concerned about the risk to life in China and has reiterated the importance of vaccination, including booster doses, to protect against hospitalization, severe disease, and death. This is especially important for older people, those with underlying medical conditions, and others who are at higher risk of severe outcomes...

:::

WHO Media Briefing – 04 January 2023

WHO Director-General's opening remarks at the media briefing – 4 January 2023

[Excerpt]

...With circulation in China so high and comprehensive data not forthcoming – as I said last week it is understandable that some countries are taking steps they believe will protect their own citizens. This data is useful to WHO and the world and we encourage all countries to share it.

Data remains essential for WHO to carry out regular, rapid and robust risk assessments of the current situation and adjust our advice and guidance accordingly.
Outside of China, one of the Omicron sub variants originally detected in October 2022 is XBB.1.5, a recombinant of two BA.2 sub-lineages.

It is on the increase in the US and Europe and has now been identified in more than 25 countries. WHO is following closely and assessing the risk of this subvariant and will report accordingly.

COVID-19 will no doubt still be a major topic of discussion, but I believe and hope that with the right efforts this will be the year the public health emergency officially ends...

Media Briefing Transcript [Excerpt; Editor’s text bolding]
00:18:12
...So, it is a risk assessment that will coming out in the coming day by our Technical Advisory Group for Virus Evolution.

We’ve had more than 13 million cases reported to WHO in the last month and we know that that’s an underestimate because surveillance has declined, plus we’ve had the holiday period. But, more concerning, we’ve had a 15% increase in deaths in the last month and, again, we know that is an underestimate because there are delays in reporting, and with the holiday period and with mixing those trends are expected to continue. So, it’s really critical that surveillance continues, that we can track the known variants and that we can better assess what is happening globally.

With regards to circulation of variants in China, I should mention the Technical Advisory Group for Virus Evolution just released a statement based on a meeting that we had yesterday, looking at circulation of SARS-CoV-2 in China. From the data that was presented to us from China CDC of the sequencing that has been done in the country, most of the viruses that are circulating in China are BA.5 sublineages but, again, we need more information in sequencing around the country, those sequences to be shared with publicly-available databases like GISAID, so that deeper analysis can be done.

00:19:47
It’s not just a matter of knowing what variants are circulating. We need the global community to assess these, to look at mutation by mutation to determine if any of these are variants that are circulating in China, but also around the world. So, there’s a lot more work that needs to be done, there’s a lot more data that needs to be shared from China but additionally around the world, so that we can track this pandemic as we enter this fourth year of this pandemic.

CL Thank you very much and over to Mike Ryan.
MR Great. Thanks, Christian. With regards to engagement with colleagues in China, we also had a meeting with high level officials from China last week and we thank the Deputy Minister from the Ministry of Health and also the Vice Administrator from the National Disease Control Authority and Director-General of China CDC, the many colleagues who engaged with us on that.

Maria has spoken to the TAG-VE and also the clinical network meeting. There will be a meeting, a briefing of our missions, the WHO Member States, tomorrow and colleagues from China will also join that. It’s an overall briefing on the COVID situation globally as outlined by the DG, including very much
the Northern Hemisphere situation, but there will also be a specific update on the COVID situation in China.

00:21:07
So, we thank Chinese colleagues for that engagement. However, as the DG has said, we still do not have complete data. There are certainly issues in terms of the criteria for recording and reporting deaths attributable to COVID-19. We believe that definition is too narrow, which requires respiratory failure in association with COVID-19 to be registered as COVID-related death. That is a very narrow definition.

We know there are difficulties in all countries, very often, in recording hospital-related admissions and use of ICU facilities but, again, we believe that the current numbers being published from China underrepresent the true impact of the disease in terms of hospital admissions, in terms of ICU admissions and particularly in terms of deaths, and we would like to see more data on a more geographic basis across China and we’ll continue to endeavour. We look forward to getting more information on that from our colleagues.

We are pleased that more data on sequencing is being uploaded and certainly getting more information from expert clinicians in China was very helpful for us to understand the clinical impact of the disease and the needs of the system. I do think, though, it is again worth reflecting because there are two lessons emerging from what we’re seeing over the last number of weeks.

00:22:29
One is even if you have existing subvariants causing your problem, if you have not good surveillance then you’re late to understand the problem in terms of its evolution of impact. If you’ve got less than optimal vaccine coverage you have more people likely to get very sick and if your health system is not constantly ready and adapted to surge, then you struggle when that surge comes, and I think China is a good example, as many other situations and countries have been over the last two years.

It’s not rocket science. This is how COVID does its damage now. If you don’t have good surveillance, good vaccine coverage and a high level of health systems readiness and resilience, you’re likely to suffer in subsequent waves of disease as immunity wanes or as new variants or subvariants emerge. And, again, we see with XBB the constant threat of the evolution or emergence of further subvariants that may have characteristics that have allowed the disease to transmit more easily or to reinfect individuals previously infected or protected by vaccination. So, it’s very important.

Also, with specific reference to China, I refer to the issue of under-recording or China as well, that we do not discourage doctors and nurses reporting on these deaths or these cases and that we have an open approach to be able to record the actual impact of the disease in society so that we can take the best action on behalf of our citizens around the world, and this is something in which every country has a stake.

But, we do recognise the increased engagement from China over the last number of weeks and specifically over the last ten days and we look forward to receiving more comprehensive data through the process of the meetings that we’re engaged in over the coming days. Thank you...
**WHO meets with Chinese officials on current COVID-19 situation**

30 December 2022 | Statement

A high-level meeting took place on 30 December between WHO and China about the current surge in COVID-19 cases, to seek further information on the situation, and to offer WHO's expertise and further support.

High-level officials from China's National Health Commission and the National Disease Control and Prevention Administration briefed WHO on China's evolving strategy and actions in the areas of epidemiology, monitoring of variants, vaccination, clinical care, communication and R&D.

WHO again asked for regular sharing of specific and real-time data on the epidemiological situation – including more genetic sequencing data, data on disease impact including hospitalizations, intensive care unit (ICU) admissions and deaths – and data on vaccinations delivered and vaccination status, especially in vulnerable people and those over 60 years old. WHO reiterated the importance of vaccination and boosters to protect against severe disease and death for people at higher risk.

WHO called on China to strengthen viral sequencing, clinical management and impact assessment, and expressed willingness to provide support on these areas, as well as on risk communications on vaccination to counter hesitancy. Chinese scientists are invited to engage more closely in WHO-led COVID-19 expert networks including the COVID-19 clinical management network. WHO has invited Chinese scientists to present detailed data on viral sequencing at a meeting of the Technical Advisory Group on SARS-CoV-2 Virus Evolution on 3 January.

WHO stressed the importance of monitoring and the timely publication of data to help China and the global community to formulate accurate risk assessments and to inform effective responses.

**PHEIC Coronavirus [COVID-19] - WHO**

*Public Health Emergency of International Concern (PHEIC)*

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

**Weekly Epidemiological and Operational updates**

Last update: 16 Dec 2022

- **Confirmed cases**: 657,977,736
- **Confirmed deaths**: 6,681,433
- **Vaccine doses administered**: 13,073,712,554

**Weekly epidemiological update on COVID-19 – 4 January 2023**

*Overview*
Globally, more than 3 million new cases and 10,000 deaths have been reported in the week of 26 December 2022 to 1 January 2023. This represents a reduction in weekly cases and deaths of 22% and 12%, respectively. In the last 28 days (5 December 2022 to 1 January 2023), over 14.5 million cases and over 46,000 new fatalities were reported globally – an increase of 25% and 21%, respectively, compared to the previous 28 days. As of 1 January 2023, over 656 million confirmed cases and over 6.6 million deaths have been reported globally.

In this edition, we include:
- The COVID-19 epidemiological update at the global and regional levels.
- An update on the circulating SARS-CoV-2 variants of concern (VOCs) and Omicron subvariants under monitoring.
- An update on hospitalizations and ICU admissions related to COVID-19.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 1 January 2023**

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 07 Jan 2023
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]
Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 07 Jan 2023]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

COVID-19 Global Targets and Progress Tracker — IMF
This tracker was last updated on May 5 2022. We have archived the information and will no longer provide updates.

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

COVID Vaccines — OCHA:: HDX
COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out

Jan 07, 2023 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 124M total confirmed cases; 2.3M total confirmed deaths
Global vaccines administered: 13.2B
Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 390M
Other Delivered (Number of Doses): 430M
Total Delivered (Number of Doses): 830M
Total Administered (Number of Doses): 570M

https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 07 Jan 2023: https://data.covid19taskforce.com/data. Notation: Last updated on: 02 Sep 2022 The global view below is complemented by country-specific dashboards here.

Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 07 Jan 2023]

:: 69.1% of the world population has received at least one dose of a COVID-19 vaccine.
:: 13.18 billion doses have been administered globally, and 1.76 million are now administered each
day.
:: **25.9%** of people in low-income countries have received at least one dose.

**Duke – Launch and Scale Speedometer**

**The Race for Global COVID-19 Vaccine Equity**

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

**Overview of donations by top 10 donating countries**

<table>
<thead>
<tr>
<th>Country</th>
<th>Pledged doses</th>
<th>Total Shipped</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>284,500,000</td>
<td>800,000,000</td>
</tr>
<tr>
<td>China</td>
<td>75,000,000</td>
<td>124,000,000</td>
</tr>
<tr>
<td>Germany</td>
<td>100,000,000</td>
<td>121,000,000</td>
</tr>
<tr>
<td>France</td>
<td>77,000,000</td>
<td>100,000,000</td>
</tr>
<tr>
<td>Spain</td>
<td>60,000,000</td>
<td>66,000,000</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>51,000,000</td>
<td>66,000,000</td>
</tr>
<tr>
<td>Italy</td>
<td>51,000,000</td>
<td>77,000,000</td>
</tr>
<tr>
<td>Australia</td>
<td>46,000,000</td>
<td>60,000,000</td>
</tr>
<tr>
<td>Japan</td>
<td>42,000,000</td>
<td>66,000,000</td>
</tr>
<tr>
<td>Canada</td>
<td>31,000,000</td>
<td>51,000,000</td>
</tr>
</tbody>
</table>

**Global COVID-19 Access Tracker**

[https://www.covid19globaltracker.org/](https://www.covid19globaltracker.org/)
U.S.: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment

HHS
News
Readout: Secretary Becerra and Commissioner Califf Speak with Pediatric Medicine Manufacturers Amid Rise of COVID-19, RSV, and Flu This Winter
December 22, 2022 | News Release

FDA
Press Announcements
FDA Roundup: January 06, 2023
:: Today, the FDA posted an update that the agency is closely monitoring the emergence of the XBB.1.5 subvariant, a SARS-CoV-2 Omicron variant that is currently estimated to account for 28% of circulating variants in the U.S. Because of its similarity to variants that are not neutralized by Evusheld (e.g., XBB), the FDA does not anticipate that Evusheld will neutralize XBB.1.5. This means that Evusheld may not provide protection against developing COVID-19 for individuals who have received Evusheld and are later exposed to XBB.1.5. However, we are awaiting additional data to verify that Evusheld is not active against XBB.1.5. We will provide further updates as new information becomes available.
:: Health care providers should inform individuals of the increased risk, compared to other variants, for COVID-19 due to SARS-CoV-2 variants not neutralized by Evusheld.
If signs and symptoms of COVID-19 occur, advise individuals to test for COVID-19 and seek medical attention, including starting treatment for COVID-19 as appropriate.

On Dec. 27, the FDA issued a warning letter to globalpharmacyplus.com for selling unapproved and misbranded drugs for use in treating or preventing COVID-19. The letter also warns the company for offering Risk Evaluation and Mitigation Strategy (REMS) drugs and narrow therapeutic index (NTI) drugs. Consumers concerned about COVID-19 should consult with their health care provider.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency
News & Press Releases
No new digest content identified.

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
News/Updates/Reports [Selected]
Ebola outbreak in Uganda, as of 3 January 2023
Epidemiological update - 5 Jan 2023

Update on SARS-CoV-2 variants: ECDC assessment of the XBB.1.5 sub-lineage
News - 5 Jan 2023

Joint ECDC-WHO/Europe mpox (monkeypox) surveillance bulletin
Epidemiological update - 4 Jan 2023

Mpxox (formerly named monkeypox) situation update, as of 3 January 2022
Epidemiological update - 4 Jan 2023

Impact of surge in China COVID-19 cases on epidemiological situation in EU/EEA
News story - 3 Jan 2023

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified. Last press release issued 31.08.2022.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

COVID-19 INDIA as on : 07 January 2023, 08:00 IST (GMT+5:30)
(↑↓ Status change since yesterday)

Active (0.01%) 2509
Discharged (98.80%) 44146534
Deaths (1.19%) 530718

COVID-19 Vaccination as on : 07 January 2023, 08:00 IST (GMT+5:30)

Total Vaccination : 2,20,13,37,209 ( 56,997 ↑)

Latest Updates
29.12.2022
Guidelines for International arrivals (updated on 29th December 2022)

Government of India – Press Information Bureau
Latest Press Releases
COVID-19 UPDATE
Posted On: 07 JAN 2023 3:23PM by PIB Delhi
- 220.13 cr Total Vaccine doses (95.14 cr Second Dose and 22.42 cr Precaution Dose) have been administered so far under Nationwide Vaccination Drive
- 56,997 doses administered in last 24 hours
- India’s Active caseload currently stands at 2,509
- Active cases stand at 0.01%
- Recovery Rate currently at 98.8%
- 204 recoveries in the last 24 hours increases Total Recoveries to 4,41,46,534
- 214 new cases recorded in the last 24 hours
- Daily positivity rate (0.11%)
- Weekly Positivity Rate (0.12%)
- 91.19 cr Total Tests conducted so far; 1,88,768 tests conducted in the last 24 hours

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

PHEIC
Mpx
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

Multi-country outbreak of mpx, External situation report #13 - 5 January 2023
Highlights
:: Since the last situation report published on 14 December 2022, 1319 new cases (1.6% increase in total cases) and 10 new deaths have been reported.
:: WHO updated the interim guidance on Surveillance, case investigation and contact tracing for mpx (monkeypox) on 22 December 2022. The document consistently replaces the name of the disease monkeypox with mpox, following the most recent WHO recommendations in this regard. It also includes a more detailed description of the investigation of possible animal exposure, as well as the potential use of wastewater surveillance for the detection of mpox transmission in communities. While WHO continues to review evidence regarding possible transmission prior to the onset of symptoms, the advice on known contacts of probable and confirmed cases has been updated. It is advised that known contacts avoid sexual contact with others during the 21-day monitoring period, regardless of their symptoms.
:: WHO also updated the mpx Case investigation form (CIF) and Case reporting form (CRF) to align with the above surveillance guidance.
:: WHO developed an Interim Guidance for Infection Prevention and Control for the management of mpx in people in situations of vulnerability such as prisons and other custodial facilities based on requests from Member States. by WHO to lend support to optimizing surveillance and other areas of monkeypox response.

::::::
**PHEIC**
**Polio**

**Polio this week as of 04 January 2023 - GPEI**

*Summary of new polioviruses this week:*
- Afghanistan: three WPV1 positive environmental samples
- Algeria: one cVDPV2 case
- Central African Rep: one cVDPV2 case and one cVDPV2 positive environmental sample
- DR Congo: two cVDPV1 cases, 11 cVDPV2 cases and two cVDPV2 positive environmental samples
- Madagascar: 11 cVDPV1 positive environmental samples

---

**UN OCHA – Current Emergencies**

*Current Corporate Emergencies*

**Afghanistan**

*No new digest content identified.*

**Northern Ethiopia**

*Ethiopia - Situation Report, 5 Jan 2023*

**Somalia**

*No new digest content identified.*

**Ukraine**

*Highlights Last Updated: 19 Dec 2022*

---

**WHO & Regional Offices** [to 07 Jan 2023]

https://www.who.int/news

*Selected News/Announcements/Statements*

4 January 2023  Statement

**TAG-VE statement on the meeting of 3 January on the COVID-19 situation in China**

30 December 2022  Statement

**WHO meets with Chinese officials on current COVID-19 situation**

28 December 2022  Statement

**Statement by Principals of the Inter-Agency Standing Committee on Afghanistan: Women’s participation in aid delivery must continue**
23 December 2022  Departmental news
**One Health Joint Plan of Action launched and presented by WHO and the Quadripartite partners**

23 December 2022  Departmental news
**One Health in G20 countries**

23 December 2022  Departmental news
**Germany supports implementing One Health Joint Plan of Action**

20 December 2022  Departmental news
**WHO updates recommendations on HPV vaccination schedule**

In a new position paper published last week, WHO has updated its recommendations for the human papillomavirus (HPV) vaccine. Of particular note, the paper states that a single-dose schedule, referred to as an alternative, off-label single-dose schedule can provide a comparable efficacy and durability of protection to a two-dose regimen. The recommendation for alternative single-dose scheduling was initially made by WHO’s independent expert advisory group, SAGE in April 2022.

The position paper is timely in the context of a deeply concerning decline in HPV vaccination coverage globally. Between 2019 and 2021, coverage of the first dose of HPV vaccination fell by 25% to 15%. This means 3.5 million more girls missed out on HPV vaccination in 2021 compared to 2019...

:::WHO Regional Offices

**Selected Press Releases, Announcements**

**WHO African Region**

:: The year 2022 in review

:: How wastewater surveillance is helping the COVID-19 fight  22 December 2022

**WHO Region of the Americas** PAHO

:: 27 Dec 2022

**Institutions from Latin America and the Caribbean to receive grants to support the elimination of communicable diseases**

Six grants will be awarded to Argentina, Brazil, Haiti, Mexico, and Peru as part of a research initiative of PAHO and TDR. Washington, D.C., 27 December 2022 (PAHO/WHO) – Six institutions from Argentina, Brazil, Haiti, México and Perú will receive research grants for topics related to Tuberculosis and other opportunistic infections in advanced...

:: 21 Dec 2022

**PAHO makes COVID-19 therapeutic available to 16 countries**

Tocilizumab is used to treat severe disease and can reduce mortality in hospitalized patients Washington, DC, 21 December (PAHO) – In an effort to increase equitable access to COVID-19 therapeutics, the Pan American Health Organization (PAHO) delivered more than 11,000 vials of a medication to improve treatment for severe and critically ill COVID...

**WHO South-East Asia Region** SEARO

No new digest content identified.
WHO European Region EURO
:: 6 January 2023   News release
Protecting the workforce through influenza and COVID-19 vaccination: perspectives from Greece
:: 27 December 2022   News release
“Listen, listen, listen” – how cooperation and communication with at-risk groups are increasing access to mpox vaccination in Latvia
:: 27 December 2022   News release
HIV prevention, diagnosis and care for Ukrainian refugees in Poland
:: 22 December 2022   News release
WHO supports Armenia through surge in rehabilitation needs caused by pandemic and conflict

WHO Western Pacific Region
:: WHO meets with Chinese officials on current COVID-19 situation
30 December 2022 | Statement
:: Solomon Islands Medical Assistance Team and WHO rapidly deploy to support Temotu Province’s COVID-19 outbreak response
30 December 2022
:: Papua New Guinea: The one-on-one personal approach goes to work for COVID-19 protection
21 December 2022

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

3 January 2023 | Yellow fever - African Region (AFRO)

19 December 2022 | Circulating vaccine-derived poliovirus type 2 (cVDPV2) - Indonesia

New WHO Publications
https://www.who.int/publications/i
Selected Titles
6 January 2023
A compendium of indicators for monitoring and evaluating progress of the road map for neglected tropical diseases 2021-2030

6 January 2023
Meeting of the Strategic Advisory Group of Experts on Immunization, October 2022: conclusions and recommendations

5 January 2023
The implications of artificial intelligence and machine learning in health financing for achieving universal...

22 December 2022

Surveillance, case investigation and contact tracing for mpox (monkeypox): interim guidance, 22 December...

22 December 2022

TRS 1044 - 56th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations

22 December 2022

Bridging the gap between ethics and decision-making in pandemics: report of the WHO Pandemic Ethics and Policy Summit, 6 December 2021

Overview
This document presents a summary report of the WHO Pandemic Ethics and Policy Summit organized by the World Health Organization (WHO) on Monday, 6 December 2021.

21 December 2022

WHO Ukraine crisis response: November 2022 bulletin

21 December 2022

Health accounts production tool (HAPT)

20 December 2022

Syndromic screening for COVID-19 of travellers crossing land borders: scientific brief, 21 December 2022

20 December 2022

The use of digital technologies to support the identification of poor and vulnerable population groups for health coverage schemes

Overview
The role of digital technologies for health financing and their potential contribution to UHC progress is receiving increased attention, although the evidence base is still very small, indicating the need for further documentation and assessments of countries’ practices. This paper seeks to contribute to gathering the evidence needed. Specifically, the paper assesses the experiences of three countries – Cambodia, India and Rwanda – to explore the use and role of digital technologies that support the identification of the poor and other vulnerable population groups. The focus is on the processes of targeting, identification and identity confirmation as important health financing-related tasks that cut across the revenue-raising and pooling functions with the purpose of providing fully- or partially subsidized coverage via publicly funded health coverage schemes.

CDC/ACIP [U.S.] [to 07 Jan 2023]
http://www.cdc.gov/media/index.html
Latest News Releases

**CDC Announces Negative COVID-19 Test Requirement from Air Passengers Entering the United States from the People’s Republic of China**

December 28, 2022  CDC is announcing today that it will implement a requirement for a negative COVID-19 test or documentation of recovery for air passengers boarding flights to the United States originating from the People’s Republic of China (PRC)...
CDC Announces Negative COVID-19 Test Requirement from Air Passengers Entering the United States from the People’s Republic of China

Africa CDC  [to 07 Jan 2023]
http://www.africacdc.org/

African Union & European Union Reinforce Digital Health Cooperation
19 December 2022 | Press Releases
... The European Commission and the African Union Commission are committed to pursuing interoperability of digital health tools, building on COVID-19 actions, to ensure the acceleration of health system strengthening and the achievement of Universal Health Coverage, bringing the health security and public health modernisation agenda to the next level...

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China  [to 07 Jan 2023]
http://en.nhc.gov.cn/

Dec 24: Daily briefing on novel coronavirus cases in China
On Dec 23, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 4,128 new cases of confirmed infections.

National Medical Products Administration — PRC  [to 07 Jan 2023]
http://english.nmpa.gov.cn/

China has 13 COVID vaccines available for second booster
2022-12-27
A total of 13 types of COVID-19 vaccines, approved for conditional marketing or emergency use, are now available as a second booster dose in China, according to experts with the State Council inter-agency task force for COVID-19 response.

China producing 60 million COVID-19 antigen test kits daily
2022-12-23
China’s daily output of antigen test kits has hit around 60 million units, as the country steps up output of anti-COVID-19 medical supplies.
Preplanned Studies: Neglected Aspects of SARS-CoV-2 Aerosol Transmission in Bathrooms of Multistory and High-Rise Buildings — Beijing Municipality, China, October 2022


Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, November 2022

Preplanned Studies: Longitudinal Participatory Surveillance Highlights Association Between Mask-Wearing and Lower COVID-19 Risk — United States, 2020

Preplanned Studies: Hospital Strain and COVID-19 Fatality — England, April 2020–March 2022

Perspectives: Infodemiology: The Science Studying Infodemic and Inforus

Perspectives: The World Needs a “Pandamic” Solution for a Pandemic Problem

Methods and Applications: Comparing COVID-19 Case Prediction Between ARIMA Model and Compartment Model — China, December 2019–April 2020

Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, October 2022

Organization Announcements

Paul G. Allen Frontiers Group [to 07 Jan 2023]
https://alleninstitute.org/news-press/

News
The interior design of our cells
January 4, 2023
Database of 200,000 cell images yields new mathematical framework to understand our cellular building blocks

Image showing the average location of 17 different internal structures inside a human cell. A new study from the Allen Institute for Cell Science builds a framework for quantifying the organization of cellular structures.
BMGF - Gates Foundation  [to 07 Jan 2023]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute  [to 07 Jan 2023]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
News: Articles and Publications
No new digest content identified.

CARB-X  [to 07 Jan 2023]
https://carb-x.org/
News
12.21.2022
**CARB-X welcomes the G20 call to action on Antimicrobial resistance**
Antimicrobial resistance (AMR) featured prominently on the G20 agenda during the past two months. In the G20 Bali Leaders’ Declaration, the G20 Heads of State and Government reiterated their commitment “to embedding a multisectoral One Health approach and enhancing global surveillance, including genomic surveillance, in order to detect pathogens and AMR that may threaten human health.” The G20 Health Ministers confirmed their support to “initiatives to catalyze AMR research and development” and published a detailed G20 Call to Action on Antimicrobial Resistance.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 07 Jan 2023]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of **Vaccines and Global Health: The Week in Review** are available here.

CEPI – Coalition for Epidemic Preparedness Innovations  [to 07 Jan 2023]
http://cepi.net/
Latest News
**CEPI CEO Dr Richard Hatchett reflects on 2022**
21 Dec 2022
[See excerpt above in Milestones]

**CEPI expands partnership with Brighton Collaboration to support safety assessment of vaccine candidates**
Broadened SPEAC programme will deliver world-leading vaccine safety guidance and support for CEPI 2.0 projects and the 100 Days Mission.

20 Dec 2022

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 07 Jan 2023]
https://cioms.ch/
News; Publications; Events
**Regulatory Systems and regulations to support clinical trial conduct in Africa**
Virtual webinar 19 January, 2023
13:30 to 15:00UTC+01:00
CIOMS and IFPMA are joining efforts to create a platform for dialog on Clinical Research in LMICs.

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 07 Jan 2023]
https://www.darpa.mil/news
News
No new digest content identified.

**Duke Global Health Innovation Center** [to 07 Jan 2023]
https://dukeghic.org/
Our Blog
**Global Health Security Agenda Needs Stronger Core to Increase Effectiveness**
The Global Accountability Platform (COVID GAP) blog series.
December 12, 2022
By Nellie BristoL

**EDCTP** [to 07 Jan 2023]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

**Emory Vaccine Center** [to 07 Jan 2023]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

**European Vaccine Initiative** [to 07 Jan 2023]
http://www.euvaccine.eu/
Latest News, Events
International day of epidemic preparedness 2022

The International Day of Epidemic Preparedness recognises the importance of being prepared for, and responding to, public health emergencies.

Dutch government pledges €17 Mio to EVI to advance malaria vaccines for pregnant women

Evidence Aid [to 07 Jan 2023]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Resources [Selected]
No new digest content identified.

Fondation Merieux [to 07 Jan 2023]
http://www.fondation-merieux.org/
News, Events  Mérieux Foundation co-organized event
No new digest content identified.

Gavi [to 07 Jan 2023]
https://www.gavi.org/
News Releases
No new digest content identified.

GHIT Fund [to 07 Jan 2023]
https://www.ghitfund.org/newsroom/press
No new digest content identified.

Global Fund [to 07 Jan 2023]
News & Stories
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 07 Jan 2023]
https://www.glopid-r.org/news/
News
No new digest content identified.
**Hilleman Laboratories**  [to 07 Jan 2023]
http://www.hilleman-labs.org/
News & Insights
White Paper, 2022
**Vaccines, Today and Tomorrow**
Hilleman Laboratories establishes pilot manufacturing facility for vaccine development in Singapore with support from Singapore Economic Development Board.

**HHMI - Howard Hughes Medical Institute**  [to 07 Jan 2023]
https://www.hhmi.org/news
Press Room
No new digest content identified.

**Human Vaccines Project**  [to 07 Jan 2023]
http://www.humanvaccinesproject.org/
News
No new digest content identified.

**IAVI**  [to 07 Jan 2023]
https://www.iavi.org/
Latest News
Selected Statements, Press Releases, Research
**FEATURES**
December 20, 2022
**IAVI Sudan vaccine arrives in Entebbe in response to Ebola outbreak**

**ICRC**  [to 015 Oct 2022]
What’s New  [Selected]
No new digest content identified.

**International Coalition of Medicines Regulatory Authorities [ICMRA]**
Selected Statements, Press Releases, Research
No new digest content identified.

**IFFIm**
http://www.iffim.org/
Press Releases/Announcements
**IFFIm funding contributes to health gains across Africa**
IFFIm provides funding for 15% of Gavi’s immunisation programmes across Africa.

IFRC [to 07 Jan 2023]
Press Releases [Selected]
Press release 26/12/2022
"At the heart of our services in Afghanistan are women and girls: as recipients and as deliverers."

Press release 22/12/2022
IFRC and IOM sign regional MoU to increase collaboration to support migrants and displaced people

Institut Pasteur [to 07 Jan 2023]
Press Documents
No new digest content identified.

ISC / International Science Council [to 07 Jan 2023]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
Current
Press releases
International Science Council deplores the exclusion of women from university education in Afghanistan and urges the Islamic Emirate of Afghanistan to reverse its decision
31.12.2022
“... urges the Islamic Emirate of Afghanistan to reverse its decision on excluding women from university education. The Council stands ready to support Afghani women and girls in meeting their aspirations through education and engagement with science and invites the Afghan authorities to meet with us to further this goal.”

Episode 5 – Preventing Crisis: Science Diplomacy and Track Two Organizations
ISC Presents: Science in Times of Crisis released its fifth and final episode. To wrap up the series, we invited ISC President Peter Gluckman and former Director-General of UNESCO Irina Bokova to discuss the realities of science diplomacy.
ISC Presents: Science in Times of Crisis is a 5 part podcast series exploring what living in a world of crisis and geopolitical instability means for science and scientists around the world. In our final, fifth episode, we are joined by the ISC President Sir Peter Gluckman and Irina Bokova, Bulgarian politician and a two-term former Director-General of UNESCO.
We explore the importance of informal and non-governmental channels in maintaining and building international scientific collaborations, the role of informal diplomatic channels such as science and
culture in building and maintaining peace, the realities of science diplomacy in practice and the importance of ordinary scientists in fostering scientific collaboration.

**International Union of Immunological Societies (IUIS)**

https://iuis.org/

*News/Events [Selected]*

‘**Viral Evolution and Evasion’, the 4th scientific session from BioNTech’s Global Scientific Exchange Program.** - Event

Thursday 26th January 2023

**IVAC** [to 07 Jan 2023]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

*Updates; Events*

*No new digest content identified.*

**IVI** [to 07 Jan 2023]

http://www.ivi.int/

*IVI News & Announcements*

**2022 Year in Review**

For our Year in Review, we rounded up 12 highlights from across the institute, including the approval of two new vaccines in Korea now on their way to the global public market, our work to increase the global supply of oral cholera vaccine through technology transfer, IVI’s ongoing partnership with the Korean Ministry of Health and Welfare to train a skilled and experienced vaccine manufacturing workforce in low- and middle-income countries, the formation of IVI’s Global Advisory Group of Experts, and more.

**Johns Hopkins Center for Health Security** [to 07 Jan 2023]

https://www.centerforhealthsecurity.org/news/center-news/

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 07 Jan 2023]

http://www.msf.org/

*Latest [Selected Announcements]*

**Ethiopia**

**Providing medical care to people across Ethiopia**

Project Update 23 Dec 2022

**Haiti**

**Supporting cholera vaccination efforts in Haiti**

Press Release 22 Dec 2022

**Tuberculosis**
**Innovative trial finds better treatment for people with drug-resistant TB**
Press Release 21 Dec 2022

**National Academy of Sciences** - USA [to 07 Jan 2023]

*News*

**Taliban’s Ban on Education for Afghan Women and Girls Will Have Potentially Disastrous Consequences Say U.S. National Academies Presidents**
December 22, 2022

The presidents of the U.S. National Academies warn that the Taliban's decision to prevent Afghan women and girls from participating in higher education or attending secondary school ignores the scientific evidence on the benefits of education for women and could have 'potentially disastrous consequences' for the future of Afghanistan.

**National Academy of Sciences** - USA [to 07 Jan 2023]

*News*

**Taliban’s Ban on Education for Afghan Women and Girls Will Have Potentially Disastrous Consequences Say U.S. National Academies Presidents**
December 22, 2022

The presidents of the U.S. National Academies warn that the Taliban's decision to prevent Afghan women and girls from participating in higher education or attending secondary school ignores the scientific evidence on the benefits of education for women and could have 'potentially disastrous consequences' for the future of Afghanistan.

**National Vaccine Program Office** - U.S. HHS [to 07 Jan 2023]
https://www.hhs.gov/vaccines/about/index.html

*Upcoming Meetings/Latest Updates*

**NVAC 2023 Meetings**
**February 2-3, 2023** NVAC Meeting

**NIH** [to 07 Jan 2023]
http://www.nih.gov/

*News Releases*

**NIH launches Home Test to Treat, a pilot COVID-19 telehealth program**
January 5, 2023 — Berks County, Pennsylvania, is first community to join partnership with local public health departments.

**New approach successfully traces genomic variants back to genetic disorders**
January 5, 2023 — NIH study shows genotype-first approach uncovers new links to genetic conditions.

**COVID-19 vaccine for children after MIS-C appears safe**
January 3, 2023 — NIH-supported study finds no serious complications following rare immune condition.
UNAIDS [to 07 Jan 2023]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
Press release
UNAIDS welcomes the announcement that Spain will be making a new €1 million contribution to UNAIDS
GENEVA, 6 January 2023—Spain’s Ministry of Health has officially announced €1 million to support UNAIDS’ work on ending AIDS by 2030 as part of the Sustainable Development Goals.

Press statement
UNAIDS welcomes Kenya’s High Court judgement in landmark case of involuntary sterilization of women living with HIV
GENEVA, 20 December 2022—UNAIDS welcomes the judgement by the High Court of Kenya at Nairobi recognizing that coerced sterilization of women living with HIV is a violation of their human rights.

UNICEF [to 07 Jan 2023]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Statement
28 December 2022
Statement by Inter-Agency Standing Committee Principals on Afghanistan
NEW YORK, 28 December 2022 - "The decision by Afghanistan’s de facto authorities to ban women from working in humanitarian non-governmental organizations is a major blow for vulnerable communities, for women, for children, and for the entire country. "Female staff are key to every aspect of the humanitarian response in Afghanistan.....
Vaccine Equity Cooperative [nee Initiative] [to 07 Jan 2023]
https://vaccineequitycooperative.org/news/
News
Jan 05, 2023
Media: Reducing the threat of vaccine-preventable diseases starts with kids
Vaccine Equity Cooperative Children’s Health Group members Alexandra Quinn, Bruce Lesley, Dr. Rhea Boyd share six top priorities for the government to protect the health and wellbeing of the nations children.

Vaccination Acceptance & Demand Initiative [Sabin] [to 07 Jan 2023]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

Vaccine Confidence Project [to 07 Jan 2023]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 07 Jan 2023]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust [to 07 Jan 2023]
https://wellcome.ac.uk/news
News. Opinion, Reports
No new digest content identified.

The Wistar Institute [to 07 Jan 2023]
Media
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 07 Jan 2023]
https://www wfpha.org/
No new digest content identified.
#WorldinTurmoil: A Timely Reflection on COVID-19 & Lessons Learned

Dec 21, 2022

Dr Rüdiger Krech, Director of the Department of Health Promotion at the World Health Organization (WHO), is interviewed by Prof. Bettina Borisch, Executive Director of the World Federation of Public Health Associations (WFPHA), and shares some reflections on pandemic preparedness, lessons learned from past pandemics, including COVID-19, the WHO’s work, and how the 17th World Congress on Public Health (WCPH2023) can shape the future of Public Health.

World Medical Association [WMA]  [to 07 Jan 2023]
Press Releases
No new digest content identified.

World Organisation for Animal Health (OIE)  [to 07 Jan 2023]
https://www.oie.int/en/
Press Releases, Statements
No new digest content identified.

ARM [Alliance for Regenerative Medicine]  [to 07 Jan 2023]
Selected Press Releases
The Alliance for Regenerative Medicine Appoints Mark Battaglini as Chief Strategy Officer
January 3, 2023

BIO  [to 07 Jan 2023]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network  [to 07 Jan 2023]
http://www.dcvmn.org/
News; Upcoming events
December 21, 2022
IABS/DCVMN Webinar on Next Generation Sequencing, Kahn et al, Biologicals, In Press

ICBA – International Council of Biotechnology Associations  [to 07 Jan 2023]
https://internationalbiotech.org/news/
News
No new digest content identified.
IFPMA [to 07 Jan 2023]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications

**IFPMA statement on WTO decision to extend the deadline to consider a waiver of intellectual property rights on COVID-19 therapeutics and diagnostics.**

21 December 2022

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) notes the decision taken by Member States at the World Trade Organization (WTO) to continue to consider an extension of a waiver of intellectual property rights on COVID-19 therapeutics and diagnostics. IFPMA expresses its disappointment that further time and energy will be devoted to a discussion that fails to address the real challenges to access.

Evidence shows there is no reason to extend a waiver on COVID-19 therapeutics and diagnostics. Instead, if adopted, the proposal will have long-term adverse effects on the current pipeline for COVID-19 therapeutics and for future pandemics. While these discussions continue, the ongoing uncertainty is unwelcome...

**Pharma trade body welcomes the multilateral framework to nurturing future biodiversity adopted at UN conference**

20 December 2022

...However, the innovative pharmaceutical industry notes with concern that, while it might seem a small detail, the lack of consideration on the fundamental difference between the biodiversity of flora and fauna versus pathogens, including genomic sequence data (or “DSI”) derived from such pathogens, is a problem for all those involved in R&D of vaccines, treatments and diagnostics to fight future outbreaks. Ensuring immediate and unhindered pathogen sharing, through a public health exemption to access and benefit (ABS) rules, is critical for the future of public health...

International Alliance of Patients’ Organizations – IAPO [to 07 Jan 2023]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/

**News**

**IGBA taking action to tackle shortages of antibiotic medicines**

Geneva, 22 December 2022

The global generic medicines industry supplies most of the world’s antibiotic medicine and is aware of the current surge in demand of these products that is leading to shortages. The surge is driven by an unusually high rate of respiratory conditions and infections that are occurring as we exit the most acute phase of the Covid-19 pandemic and, in many countries, an unusually high rate of respiratory conditions and infections among children. Demand has also increased due to changes in prescribing protocols, leading to a much higher number of prescriptions being issued for certain antibiotic medicines...

PhRMA [to 07 Jan 2023]
Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases
Nirsevimab US regulatory submission accepted for the prevention of RSV lower respiratory tract disease in infants and children up to age 24 months
5 January 2023
:: If FDA approved, nirsevimab would be the first single-dose RSV preventative option for the broad newborn and infant population in the US
:: Submission supported by comprehensive clinical trial programme, which demonstrated protection against RSV disease through the RSV season

Bharat Biotech
Press Releases
iNCOVACC® is now available on CoWin, priced at INR 800+GST for Private Markets and INR 325+GST for Governments
Dec 27
:: iNCOVACC® to be rolled out as booster dose for those above 18 years of age.
:: iNCOVACC® is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule, and as a heterologous booster dose.

BioCubaFarma – Cuba
Últimas Noticias - Website not responding at inquiry

Biological E
News - No new digest announcements identified

BioNTech
Press Releases
23 December 2022
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

23 December 2022
BioNTech and Fosun Pharma Announce Full Regulatory Approval of their Mono- and Bivalent COVID-19 Vaccine COMIRNATY® in Individuals 12 Years and Older in Hong Kong

22 December 2022
BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

21 December 2022
**Update on First BioNTainer for African-based mRNA Manufacturing Facility**

21 December 2022

**BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163**

**Boehringer**
*Press Releases* - No new digest announcements identified

**CanSinoBIO**
*News* - Website not responding at inquiry

**CIGB**
*Latest News* - No new digest announcements identified

**Cinnagen**
*Recent News* - No new digest announcements identified

**Clover Biopharmaceuticals** - China
*News* - No new digest announcements identified

**Curevac [Bayer Ag – Germany]**
*News* January 6, 2023

**CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs**
:: Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies
:: All candidates use CureVac’s advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low doses

**Gamaleya National Center**
*Latest News and Events* - See Russia above.

**GSK**
*Press releases for media*
21 December 2022

**VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain**
* - SARS-CoV-2 spike protein vaccine is the first and only protein-based variant COVID-19 booster vaccine approved in Great Britain and the EU

**IMBCAMS**, China
*Home* - Website not responding at inquiry

**Janssen/JNJ**
*Press Releases* - No new digest announcements identified
Medicago
*Media* - No new digest announcements identified

Merck
*News releases* - No new digest announcements identified

Moderna
*Press Releases*
05 January, 2023
**Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics**
:: Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions
:: CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments

04 January, 2023
**Moderna to Acquire OriCiro Genomics**
:: OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines

21 December, 2022
**Moderna Finalizes Strategic Partnership with UK Government**
:: Facility to enable access to domestically manufactured mRNA respiratory vaccines, pending regulatory assessment and licensure
:: The ten-year strategic partnership is expected to provide the UK public with response capabilities to ensure future preparedness in light of the COVID-19 pandemic
Moderna is expanding its presence in the UK through investments in R&D activities and capabilities

Nanogen
*News* - No new digest announcements identified

Novartis
*News* - No new digest announcements identified

Novavax
*Press Releases*
Jan 5, 2023
**Spanish, Italian and French Health Authorities Expand Recommendations for Use of Novavax COVID-19 Vaccine**

Dec 30, 2022
**Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates**

Pfizer
*Recent Press Releases*
01.06.2023
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children

12.28.2022
U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases -- No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News - No new digest announcements identified

Sinovac
Press Releases
Study Proves the Immunogenicity and Safety of Co-administration with SINOVAC’s WHO Prequalified Varicella and Hepatitis A Vaccines to 1 Year Old
2023/01/06

SK Biosciences
Press Releases - No new digest announcements identified

Takeda
Newsroom - No new digest announcements identified

Valneva
Press Releases
December 30, 2022
Valneva Reports Further Heterologous Booster Data for its Inactivated COVID-19 Vaccine

December 23, 2022
Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate

Vector State Research Centre of Viralology and Biotechnology
Home - Website not responding [404 error]
Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 4
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 25, Number 1: E1-87
https://journalofethics.ama-assn.org/issue/segregation-health-care

Segregation in Health Care
Structural racism is deeply embedded in US health care. Legally sanctioned racial segregation in hospitals ended with the Civil Rights Act of 1964, with fiscally incentivized enforcement through Medicare payment structures implemented in 1966. Yet, practices such as sorting patients by insurance status still perpetuate de facto racial and class segregation, especially in academic health centers. This theme issue investigates a clear health justice demand to definitively end continued normalization of structural racism everywhere we care for our ill and injured. This issue considers sources of ethical, clinical, public health, and educational responsibilities to remediate health injustice where students and trainees learn their professions and internalize professional norms.
From the Editor  Jan 2023

**A Call for Health Care Desegregation**
Denisse Rojas Marquez, MD, MPP and Hazel Lever, MD, MPH

Practices of sorting patients into different tracks of care within a facility or system by insurance status, race, and other social markers persist.

**American Journal of Infection Control**
January 2023  Volume 51Issue 1p1-120
http://www.ajicjournal.org/current

*State of the Science Review*
**Effectiveness of antimicrobial stewardship interventions on early switch from intravenous-to-oral antimicrobials in hospitalized adults: A systematic review**
Yusuf M. Garwan, Muath A. Alsalloum, Abrar K. Thabit, Jimmy Jose, Khalid Eljaaly
Published online: May 26, 2022  p89-98

**American Journal of Preventive Medicine**
January 2023  Volume 64  Issue 1p1-148
https://www.ajpmonline.org/current

*Research Briefs*
**Mortality by Education Before and During the COVID-19 Pandemic, U.S., 2017–2020**
Emily C. Marlow, Ahmedin Jemal, Blake Thomson,...Jingxuan Zhao, Rebecca L. Siegel, Farhad Islami
Published online: October 13, 2022  p105-116

*Current Issues*
**Failing Grade: The Pandemic Legacy of HHS**
Eli Y. Adashi, I. Glenn Cohen
Published online: August 30, 2022  p142-144

**American Journal of Public Health**
January 2023  113(1)
http://ajph.aphapublications.org/toc/ajph/current

*EDITORIALS*
**Wastewater Surveillance—“Messy” Science With Public Health Potential**
Infections, Surveillance, COVID-19, Statistics/Evaluation/Research, Community Health, Epidemiology
James W. Keck and Scott M. Berry
113(1), pp. 6–8

*PERSPECTIVES FROM THE SOCIAL SCIENCES*
**Antiracism and Community-Based Participatory Research: Synergies, Challenges, and Opportunities**
Other Statistics/Evaluation/Research, Statistics/Evaluation/Research, Community Health, Analytic Essay
Paul J. Fleming, Lisa Cacari Stone, Melissa S. Creary, Ella Greene-Moton, Barbara A. Israel, Kent D. Key, Angela G. Reyes, Nina Wallerstein and Amy J. Schulz
113(1), pp. 70–78

OPEN-THEMED RESEARCH
SARS-CoV-2 Infection, Hospitalization, and Death in Vaccinated and Infected Individuals by Age Groups in Indiana, 2021–2022
Immunization/Vaccines, COVID-19, Research Article
Wanzhu Tu, Pengyue Zhang, Anna Roberts, Katie S. Allen, Jennifer Williams, Peter Embi and Shaun Grannis

American Journal of Tropical Medicine and Hygiene
Volume 107 (2022): Issue 6 (Dec 2022)
Perspectives  Open access
Beyond the Unknown: A Broad Framing for Preparedness for Emerging Infectious Threats
Rebecca C. Christofferson and Stephania A. Cormier
Volume 107: Issue 6
DOI: https://doi.org/10.4269/ajtmh.22-0341
Page(s): 1159–1161

Open access
Toward a New Paradigm of North–South and South–South Partnerships for Pandemic Preparedness: Lessons Learned from COVID-19 and Other Outbreaks
Sabin Nsanzimana et al.
Volume 107: Issue 6
DOI: https://doi.org/10.4269/ajtmh.22-0466
Page(s): 1162–1165

Understanding Factors Influencing Polio Vaccine Uptake in Ghana—Developing Meaningful Community Mobilization and Engagement Strategies in Collaboration with Religious Leaders
Anna-Leena Lohiniva et al.
Volume 107: Issue 6
DOI: https://doi.org/10.4269/ajtmh.22-0271
Page(s): 1345–1350

Annals of Internal Medicine
December 2022  Volume 175, Issue 12
http://annals.org/aim/issue
Original Research
Contact Tracing and Exposure Investigation in Response to the First Case of Monkeypox Virus Infection in the United States During the 2022 Global Monkeypox Outbreak
FREE
Erica S. Shenoy, MD, PhD, Sharon B. Wright, MD, MPH, Deborah N. Barbeau, MD, PhD, MSPH, ... et al.
Participant Recruitment From Low- and Middle-Income Countries for Pivotal Trials of Drugs Approved by the U.S. Food and Drug Administration - A Cross-Sectional Analysis
Fareed A. Awan, PhD, Andrew B. Becker, PhD, Yuetong Wang, BSc, and Jonathan Kimmelman, PhD
Pages:1675–1684

Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era
FREE
George N. Ioannou, BMBCh, MS, Amy S.B. Bohnert, PhD, Ann M. O’Hare, MD, ... et al.
Pages:1693–1706
Position Papers

Health Care During Incarceration: A Policy Position Paper From the American College of Physicians
FREE
Newton E. Kendig, MD, Renee Butkus, BA, Suja Mathew, MD, and ... et al.
Pages:1742–1745

Artificial Intelligence – An International Journal
Volume 314  January 2023
[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 07 Jan 2023)
[No new digest content identified]

BMJ Global Health
January 2023 - Volume 8 - 1
https://gh.bmj.com/content/7/12
Analysis
Matthew R Boyce, Erin M Sorrell, Claire J Standley

Practice
Investing in preparedness for rapid detection and control of epidemics: analysis of health system reforms and their effect on 2021 Ebola virus disease epidemic response in Guinea
(4 January, 2023)
Mory Keita, Ambrose Talisuna, Dick Chamla, Barbara Burmen, Mahamoud Sama Cherif, Jonathan A Polonsky, Samuel Boland, Boubacar Barry, Samuel Mesfin, Fodé Amara Traoré, Jean Traoré, Jean Paul
Mobile Money and the importance of timely, complete payments to frontline health campaign workers in the fight to eradicate polio: pilot experience from a World Health Organization digital payment platform in Africa

In response to the increase in vaccine-derived poliovirus type 2 in Côte d’Ivoire, Mali, and many other African countries from 2017 to 2019, concentrated efforts are needed to improve the effectiveness of vacc...

Authors: Ahmed Hamani, Idil Hussein Jama, Mian Amoakan Yves Roland, Leah Wanjeri, Abena Aboagyewaa Oppon-Kusi, Dorcas Karimi, Patsy Kiconco, Oromena Edwin Akpotu and Mahafous Saka

Citation: BMC Health Services Research 2023 23:16

Introduction and implementation of an immunization information system in the Indonesian province of Daerah Istimewa Yogyakarta: lessons for scaling-up

Immunization is critical to saving children from infections. To increase vaccination coverage, valid and real-time data are needed. Accordingly, it is essential to have a good report system that serves as defa...

Authors: Sulistyawati Sulistyawati, Trisno Agung Wibowo, Rokhmayanti Rokhmayanti, Andri Setyo Dwi Nugroho, Tri Wahyuni Sukses, Siti Kurnia Widi Hastuti, Surahma Asti Mulasari and Marta Feletto

Citation: BMC Health Services Research 2023 23:12

Applications, benefits and challenges of telehealth in India during COVID-19 pandemic and beyond: a systematic review

India, the seventh-largest country in the world and the second-most populated faces enormous challenges when it comes to healthcare. The country’s healthcare system was close to collapse due to the detrimental...

Authors: Eslavath Rajkumar, Aswathy Gopi, Aditi Joshi, Aleena Elizabeth Thomas, N. M. Arunima, Gosetty Sri Ramya, Prachi Kulkarni, P. Rahul, Allen Joshua George, John Romate and John Abraham

Citation: BMC Health Services Research 2023 23:7

Implementation barriers and facilitators to a COVID-19 intervention in Bangladesh: The benefits of engaging the community for the delivery of the programme

BRAC (Bangladesh Rural Advancement Committee), the largest NGO globally, implemented a community-based comprehensive social behavior communication intervention to increase community resilience through preventi...

Authors: Fahmida Akter, Malika Tamim, Avijit Saha, Imran Ahmed Chowdhury, Omor Faruque, Animesh Talukder, Mohiuddin Ahsanul Kabir Chowdhury, Monzur Morshed Patwary, Albaab-Ur Rahman, Morseda Chowdhury and Malabika Sarker

Citation: BMC Health Services Research 2022 22:1590

Content type: Research Published on: 28 December 2022
BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 07 Jan 2023)
[No new digest content identified]

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 07 Jan 2023)

**Attitudes and values among the Swedish general public to using human embryonic stem cells for medical treatment**
The use of human embryonic stem cells (ES cells) for the development of medical therapies is surrounded with moral concerns. The aim of this study was to assess the public’s attitudes toward the use of ES cell...
Authors: Åsa Grauman, Mats Hansson, Dag Nyholm, Elena Jiltsova, Håkan Widner, Trinette van Vliet and Jennifer Drevin
Citation: BMC Medical Ethics 2022 23:138
Content type: Research Published on: 22 December 2022

**Effect of medical researchers’ creative performance on scientific misconduct: a moral psychology perspective**
In recent years, some researchers have engaged in scientific misconduct such as fabrication, falsification, and plagiarism to achieve higher research performance. Considering their detrimental effects on indiv...
Authors: Na Zhang, Mingxuan Guo, Chunhua Jin and Zhen Xu
Citation: BMC Medical Ethics 2022 23:137
Content type: Research Published on: 18 December 2022

BMC Medicine
http://www.biomedcentral.com/bmcmmed/content
(Accessed 07 Jan 2023)

Human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS) is still among the leading causes of disease burden and mortality in sub-Saharan Africa (SSA), and the world is not on track to m...
Authors: Emily Haeuser, Audrey L. Serfes, Michael A. Cork, Mingyou Yang, Hedayat Abbastabar, E. S. Abhilash, Maryam Adabi, Oladimeji M. Adebayo, Victor Adekanmbi, Daniel Adedayo Adeyinka, Saira Afzal, Bright Opoku Ahinkorah, Keivan Ahmadi, Muktar Beshir Ahmed, Yonas Akalu, Rufus Olusola Akinyemi...
Citation: BMC Medicine 2022 20:488
Content type: Research article Published on: 19 December 2022

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
**An integrative literature review on the impact of COVID-19 on maternal and child health in Africa**

Africa has the highest rates of maternal deaths globally which have been linked to poorly functioning health care systems. The pandemic revealed already known weaknesses in the health systems in Africa, such a...

Authors: Ephraim Kumi Senkyire, Olabanji Ewetan, Dominic Azuh, Ernestina Asiedua, Rebecca White, Margaret Dunlea, Mary Barger and Magdalena Ohaja

Citation: BMC Pregnancy and Childbirth 2023 23:6

Content type: Research Published on: 4 January 2023

**Pertussis and influenza immunization: perceived attitude and decision of postpartum patients**

Vaccination of pregnant patients with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) and influenza vaccine during influenza season can reduce maternal and fetal morbidity and mortali...

Authors: Nutan B. Hebballi, Tayler Parker, Elisa I. Garcia, Dalya M. Ferguson, Susan Lesser, KuoJen Tsao, Maryam Broussard and Susan H. Wootton

Citation: BMC Pregnancy and Childbirth 2022 22:975

Content type: Research Published on: 28 December 2022

**The effectiveness of pay-it-forward in addressing HPV vaccine delay and increasing uptake among 15–18-year-old adolescent girls compared to user-paid vaccination: a study protocol for a two-arm randomized controlled trial in China**

Human papillomavirus (HPV) vaccination could prevent cervical and other HPV-associated cancers attributable to vaccine-associated HPV types. However, HPV vaccination coverage among women aged 9–18 years old is...

Authors: Yifan Li, Chuanyu Qin, Shengyue Qiu, Yu He, Linchuan Pang, Xiaolan Xu, Vivian Wan-Cheong Yim, Shenglan Tang, Heng Du, Wenfeng Gong, Fan Yang, Joseph D. Tucker, Weiming Tang, Yun Wang, Leesa Lin, Mark Jit...

Citation: BMC Public Health 2023 23:48

Content type: Study protocol Published on: 7 January 2023

**The impact of information sources on COVID-19 vaccine hesitancy and resistance in sub-Saharan Africa**

Vaccination remains the most powerful weapon against the emergence of new variants of coronavirus (COVID-19). However, false information about COVID-19 vaccines through various platforms including social media...

Authors: Uchechukwu L. Osuagwu, Khathutshelo P. Mashige, Godwin Oversoni-Ogbomo, Esther Awazzi Envuadu, Emmanuel Kwasi Abu, Chundung Asabe Miner, Chikasirimobi G. Timothy, Bernadine N. Ekpenyong, Raymond Langsi, Onyekachukwu M. Amiebenomo, Richard Oloruntoba, Piwuna Christopher Goson, Deborah Donald Charwe, Tanko Ishaya and Kingsley E. Agho

Citation: BMC Public Health 2023 23:38

Content type: Research Published on: 6 January 2023
Spatial analysis of measles vaccination coverage in the State of São Paulo
Measles is a contagious viral disease that seriously affects children. The measles vaccine is widely recommended in Brazil and in the world; however, the disease remains relevant for the health authorities. Th...
Authors: Ysabely de Aguiar Pontes Pamplona, Anderson Marcos Vieira do Nascimento, Ricardo Alves de Olinda, Carolina Luisa Alves Barbieri, Alfésio Luís Ferreira Braga and Lourdes Conceição Martins
Citation: BMC Public Health 2023 23:29
Content type: Research Published on: 5 January 2023

Worries, beliefs and factors influencing perinatal COVID-19 vaccination: a cross-sectional survey of preconception, pregnant and lactating individuals
COVID-19 vaccines are recommended for pregnant and lactating individuals, and there is substantial evidence for their safety and effectiveness. As the pandemic continues, information on worries and beliefs sur...
Authors: Serine Ramlawi, Katherine A. Muldoon, Sandra I. Dunn, Malia S. Q. Murphy, Alysha L. J. Dingwall-Harvey, Ruth Rennicks White, Romina Fakhraei, Shi Wu Wen, Mark C. Walker, Deshayne B. Fell, Tali Bogler and Darine El-Chaâr
Citation: BMC Public Health 2022 22:2418
Content type: Research Published on: 23 December 2022

Messaging preferences among Florida caregivers participating in focus groups who had not yet accepted the HPV vaccine for their 11- to 12-year-old child
In the United States, human papillomavirus (HPV) vaccination rates remain low. The President’s Cancer Panel suggests that effective messaging about the HPV vaccination focus on the vaccine’s safety, efficacy, abi...
Authors: Stephanie A. S. Staras, Carma L. Bylund, Michaela D. Mullis, Lindsay A. Thompson, Jaclyn M. Hall, Marta D. Hansen and Carla L. Fisher
Citation: BMC Public Health 2022 22:2413
Content type: Research Published on: 22 December 2022

Overcoming barriers and enhancing facilitators to COVID-19 vaccination in the Hispanic community
Hispanic communities in the United States have been disproportionately affected by COVID-19 infections, hospitalizations, and death. Vaccination against COVID-19 is critical for controlling the pandemic; howev...
Authors: Ramey Moore, Martha O. Rojo, Rachel S. Purvis, Luis Paganelli Marin, Judith Yáñez, Sharon Reece, Cheryl Wells, Brittany Vaughn and Pearl A. McElfish
Citation: BMC Public Health 2022 22:2393
Content type: Research Published on: 20 December 2022

BMC Research Notes
http://www.biomedcentral.com/bmcresearchnotes/content
(Accessed 07 Jan 2023)
[No new digest content identified]
BMJ Evidence-Based Medicine
December 2022 - Volume 27 - 6
https://ebm.bmj.com/content/27/6
[Reviewed earlier]

BMJ Open
November 2022 - Volume 12 - 11
https://bmjopen.bmj.com/content/12/11
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 101(1); 2023 Jan 1
https://www.ncbi.nlm.nih.gov/pmc/issues/424624/
Research
Hospital-based antimicrobial stewardship, India
Sonam Vijay, V Ramasubramanian, Nitin Bansal, VC Ohri, Kamini Walia
doi: 10.2471/BLT.22.288797
PMCID: PMC9795386

Tuberculosis treatment outcomes and patient support groups, southern India
Bull World Health Organ. 2023 Jan 1; 101(1): 28–35A. Published online 2022 Nov 15.
doi: 10.2471/BLT.22.288237
PMCID: PMC9795383

Systematic Reviews
Overuse of medications in low- and middle-income countries: a scoping review
Loai Albarqouni, Sujeewa Palagama, Julia Choi, Priatharsini Sivathanthojathy, Thanya Pathirana, Mina Bakhit, Morteza Arab-Zozani, Respati Ranakusuma, Magnolia Cardona, Anna Scott, Justin Clark, Claire Friedemann Smith, Emmanuel Efa, Eleanor Ochodo, Ray Moynihan, & the Overdiagnosis and Overuse of Healthcare Services in LMICs Network
doi: 10.2471/BLT.22.288293
PMCID: PMC9795388

Cell
Jan 05, 2023 Volume 186 Issue 1 p1-232
https://www.cell.com/cell/current
Leading edge
Voices
Polio eradication: Addressing the hurdles on the last mile
Kimberly M. Thompson, et al.
In 1988, the World Health Assembly committed to eradicate poliomyelitis, a viral disease that can cause permanent paralysis. Today, only type 1 of the three wild poliovirus types remains circulating in limited geographic areas following widespread use of different poliovirus vaccines. While we are close to zero new cases of wild polio, it is a fragile situation, and there are many remaining and new hurdles to overcome. Here, experts discuss how to address them.

**Review**
**Featured Article**

**Phage therapy: From biological mechanisms to future directions**
Steffanie A. Strathdee, Graham F. Hatfull, Vivek K. Muralik, Robert T. Schooley

Open Access

Phage therapy has undergone a revitalization in the last 7 years, and a growing number of clinical trials are underway. This review provides a comprehensive view on the state of the art in phage therapy, covering biological mechanisms, clinical applications, remaining challenges, and future directions.

**Child Care, Health and Development**
Volume 49, Issue 1  Pages: 1-209  January 2023
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

**Clinical Pharmacology & Therapeutics**
Volume 113, Issue 1  Pages: 1-195  January 2023
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

**Innovations in Biosimilars**
Editorial

**Advancing Innovations in Biosimilars**
Yow-Ming Wang, David G. Strauss
Pages: 11-15
First Published: 22 December 2022

**Articles**

**Contribution of Real-World Evidence in European Medicines Agency’s Regulatory Decision Making**
Elisabeth Bakker, Kelly Plueschke, Carla J. Jonker, Xavier Kurz, Viktoria Starokozhko, Peter G. M. Mol
Pages: 135-151
First Published: 17 October 2022

**Clinical Therapeutics**
December 2022  Volume 44  Issue 12  p1549-1632
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]
Assessing the impact of aid on public health expenditure in aid recipient countries
Yoojin Lim, Youngwan Kim, Daniel Connolly
e12635
First Published: 09 April 2022

COVID-19 vaccination: Willingness and practice in Bangladesh
Avinno Faruk, Ishmam Al Quddus
e12645
First Published: 16 May 2022

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 5 - October 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]
**Ethics & International Affairs**

Summer 2022 (36.2) | July 29, 2022
[Read more](https://www.ethicsandinternationalaffairs.org/2022/summer-2022-36-2/)

**ROUNDTABLE: VULNERABLE COMMUNITIES, FUTURE GENERATIONS, AND POLITICAL REPRESENTATION IN CLIMATE POLICY AND PRACTICE**

... This roundtable collection is motivated by the following question: How can the voices of vulnerable communities and future generations be adequately and fairly represented within climate change policy and practice? The contributions address this question from several perspectives. Simon Caney focuses on global governance institutions to protect the interests of future generations, considering specific proposals and asking what criteria should be used to evaluate them. Stephen Gardiner’s essay builds on his previous work calling for a global constitutional convention, elaborating on the proposal and addressing objections to it. Colin Hickey argues that it is necessary to consider more informal modes of representing vulnerable communities and future generations, such as through grassroots organizations. In our contribution, we argue that the interests of future generations are best represented in deliberations around climate policy and practice by those already most vulnerable to the impacts of climate change. Marco Grix and Krushil Watene’s essay argues that the representation of climate-vulnerable communities and future generations—in particular, Indigenous peoples—must ensure the protection of the complex network of social practices that guide how vulnerable communities respond to climate change...

**Ethics, Medicine and Public Health**

Volume 25  December 2022
[Read more](https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/25/suppl/C)

**The European Journal of Public Health**

Volume 32, Issue 6, December 2022
[Read more](https://academic.oup.com/eurpub/issue/32/6)
Expert Review of Vaccines
Vol 21 (12) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
Volume 101, Number 6  November/December 2022
https://www.foreignaffairs.com/issues/2022/101/6
[Reviewed earlier]

Forum for Development Studies
Volume 49, 2022 - Issue 3
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genetics in Medicines
Volume 25, Issue 1  Pages A1-A10, 1-166 (January 2023)
https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/1
Review article  Full text access
Models of communication for polygenic scores and associated psychosocial and behavioral effects on recipients: A systematic review
Courtney K. Wallingford, Hannah Kovilpillai, Chris Jacobs, Erin Turbitt, ... Tatiane Yanes
Pages 1-11

Research article  Full text access
Genetics professionals are key to the integration of genetic testing within the practice of frontline clinicians
Maren T. Scheuner, Paloma Sales, Katherine Hoggatt, Ning Zhang, ... Michael J. Kelley
Pages 103-114

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 07 Jan 2023]
[No new digest content identified]

Global Health Action
Volume 16, Issue 1 (2023)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
Article
Indirect effects of COVID-19 on maternal and child health in South Africa
Community engagement and involvement in managing the COVID-19 pandemic among urban poor in low- and middle-income countries: a systematic scoping review and stakeholders mapping

Krushna Chandra Sahoo, Mili Roopchand Sahay, Shubhankar Dubey, Subhasish Nayak, Sapna Negi, Pranab Mahapatra, Debdutta Bhattacharya, Mariam Otmani Del Barrio & Sanghamitra Pati

Interventions to Improve the Reproductive Health of Undocumented Female Migrants and Refugees in Protracted Situations: A Systematic Review

Silvana Larrea-Schiavon, Lucía M. Vázquez-Quesada, Lindsay R. Bartlett, Nayeli Lam-Cervantes, Pooja Sripad, Isabel Vieitez and Liliana Coutiño-Escamilla

Evidence from a systematic review shows that subsidizing health care, strengthening health services, and implementing educational interventions have positive effects on undocumented migrant women and female refugees' sexual and reproductive health outcomes.

Preexposure Prophylaxis Among Pregnant and Lactating People in 18 PEPFAR-Supported Countries: A Review of HIV Strategies and Guidelines

Sheena Sharifi Abadan, Liz Hawryluk, Michele Montandon, Nicole Flowers, Jane Schueller, Robyn Eakle, Pragna Patel, Michelle S. Chevalier, Sangeeta Rana and Anouk Amzel

The use of preexposure prophylaxis (PrEP) is a safe, efficacious method to prevent HIV infections among pregnant and lactating people (PLP) and their infants. Despite growing support for PrEP use among PLP and notable changes in national policies, many policy gaps persist.

China: Management of COVID-19 Downgraded

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 07 Jan 2023]
Effective January 8, 2023, the preventive and control measures for the top Class A infectious diseases under Chinese law will no longer apply to COVID-19, China’s National Health Commission (NHC) announced on December 26, 2022. Previously, on January 20, 2020, the NHC had announced that the State Council had approved listing COVID-19, then called “novel ... Continue reading “China: Management of COVID-19 Downgraded”

Contributor: Zhang, Laney
Date: 2023-01-06

**Global Public Health**
Volume 17, Issue 11 (2022)
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]

**Globalization and Health**
http://www.globalizationandhealth.com/
[Accessed 07 Jan 2023]

*Health system to response to economic sanctions: global evidence and lesson learned from Iran*
Sanctions have direct and indirect impacts on people's lives. Therefore, the health systems of countries targeted by sanctions must respond effectively. This study proposes a set of mitigating measures and res...
Authors: Haniye Sadat Sajadi and Reza Majdzadeh
Citation: Globalization and Health 2022 18:107
Content type: Research Published on: 29 December 2022

**Health and Human Rights**
Volume 24, Issue 1, June 2022
[Reviewed earlier]

**Health Economics, Policy and Law**
Volume 18 - Issue 1 - January 2023
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

**Health Policy and Planning**
Volume 37, Issue 10, December 2022
https://academic.oup.com/heapol/issue/37/10
[Reviewed earlier]

**Health Research Policy and Systems**
http://www.health-policy-systems.com/content
Tools for assessing health research partnership outcomes and impacts: a systematic review
To identify and assess the globally available valid, reliable and acceptable tools for assessing health research partnership outcomes and impacts.
Citation: Health Research Policy and Systems 2023 21:3
Content type: Review Published on: 5 January 2023

The whole-of-society approach of mass COVID-19 vaccination in China: a qualitative study
Many countries have an inefficient vaccination system, which hinders global exit from the COVID-19 pandemic. It is vital to summarize COVID-19 vaccination practices in countries with high vaccination coverage ...
Authors: Qian Wang, Zhiqiang Qu, Shiyi Tu, Xi Chen and Zhiyuan Hou
Citation: Health Research Policy and Systems 2022 20:142
Content type: Research Published on: 30 December 2022

Strengthening research ethics governance and regulatory oversight in Central America and the Dominican Republic in response to the COVID-19 pandemic: a qualitative study
Good governance and regulatory supervision are required to conduct research in an international public health emergency context and to ensure compliance with ethical standards. The "Strengthening research ethics...
Authors: Julio Arturo Canario Guzmán, Jessie Orlich, Renata Mendizábal-Cabrera, Argentina Ying, Claude Vergès, Eleonora Espinoza, Mario Soriano, Elsy Cárcamo, Briana Beltrán, Eddys Rafael Mendoza Marrero, Reyna Sepulveda, Claudia Nieto Anderson, Nicole Feune de Colombi, Roxana Lescano, Eddy Pérez-Then, Trudie Lang...
Citation: Health Research Policy and Systems 2022 20:138
Content type: Research Published on: 23 December 2022

Barriers to sustainable health research leadership in the Global South: Time for a Grand Bargain on localization of research leadership?
Strong Global South (GS) health research leadership, itself both dependent on and a requisite for strong health research systems, is essential to generate locally relevant research and ensure that evidence is ...
Authors: Marian Abouzeid, Ahlam Muthanna, Iman Nuwayhid, Fadi El-Jardali, Phil Connors, Rima R. Habib, Shahram Akbarzadeh and Samer Jabbour
Citation: Health Research Policy and Systems 2022 20:136
Content type: Commentary Published on: 19 December 2022

Human Gene Therapy
Volume 33, Issue 23-24 / December 2022
https://www.liebertpub.com/toc/hum/33/23-24
[New issue; No digest content identified]
Humanitarian Practice Network
https://odihpn.org/  
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022  
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList  
[Reviewed earlier]

Immunity
Dec 13, 2022  Volume 55  Issue 12  p2211-2470  
https://www.cell.com/immunity/current  
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/  
[Accessed 07 Jan 2023]  
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content  
[Accessed 07 Jan 2023]  
**Role of social organization engagement in high-risk groups intervention against HIV/AIDS: a case study from 176 cities of China**  
Authors: Zhiwei Leng, Sha Sha, Shuyu Dai, Xuehui Meng, Jinfeng Li, Junyi Jin, Wenlin Zheng, Weihua Yang, Chuanju Mao, Zhenzhong Wang, Lijun Zhang, Peng Wang, Tao Yang and Weizhong Yang  
Content type: Case Study 28 December 2022

International Health
Volume 14, Issue 6, November 2022  
https://academic.oup.com/inthealth/issue/14/6  
[Reviewed earlier]

International Human Rights Law Review
Volume 11 (2022): Issue 1 (Jun 2022)  
https://brill.com/view/journals/hrlr/11/1/hrlr.11.issue-1.xml  
**Table of Contents**  
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Awareness and attitude of domestic workers toward COVID-19 and vaccination: a cross-sectional study
Riti Thapar Kapoor
264-269
DOI: 10.18203/2394-6040.ijcmph20223555

International Journal of Epidemiology
Volume 51, Issue 6, December 2022
https://academic.oup.com/ije/issue
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 15 Issue 3, 2022
https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/3
Special Issue: Children, young people and their international human right to healthcare
[Reviewed earlier]

JAMA
January 3, 2023, Vol 329, No. 1, Pages 5-104
https://jamanetwork.com/journals/jama/currentissue
Caring for the Critically Ill Patient
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial
Writing Committee for the REMAP-CAP Investigators
free access
This secondary analysis of an ongoing adaptive platform trial examines the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes.

Editorial
Long-term Follow-up After Critical COVID-19 REMAP-CAP Revisited
Michael L. Barnett, MD, MS; Paul E. Sax, MD

Research Letter
COVID-19 and Excess All-Cause Mortality in the US and 20 Comparison Countries, June 2021-March 2022
Alyssa Bilinski, PhD; Kathryn Thompson, MHA; Ezekiel Emanuel, MD, PhD
free access
This study compares the COVID-19 per capita overall and excess mortality rates in the US vs rates for 20 Organization for Economic Co-operation and Development countries and the timing of any increases in excess mortality between June 2021 and December 2021 (Delta) and December 2021 to March 2022 (Omicron).
Special Communication

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

Rajesh T. Gandhi, MD; Roger Bedimo, MD; Jennifer F. Hoy, MBBS; et al.

This guideline from the International Antiviral (formerly AIDS) Society–USA updates practice recommendations for managing HIV infection, including when to change antiviral regimens; use of preexposure prophylaxis to prevent infection in at-risk persons; care of pregnant persons with HIV, people aging with HIV, and people with substance use disorder and HIV; and new challenges in people with HIV, including COVID-19 and monkeypox virus infection.

Viewpoint

Urgent Need for Next-Generation COVID-19 Vaccines

Peter W. Marks, MD, PhD; Philip A. Gruppuso, MD; Eli Y. Adashi, MD, MS

This Viewpoint argues that the development of a distinctly improved generation of SARS-CoV-2 vaccines is paramount to offering a greater breadth and depth of protection for a longer duration against COVID-19 disease.

Audio: Urgent Need for Next-Generation COVID-19 Vaccines

Editorial

Public Access to Scientific Research Findings and Principles of Biomedical Research—A New Policy for the JAMA Network

Kirsten Bibbins-Domingo, PhD, MD, MAS; Brian Shields, MBA; John Z. Ayanian, MD, MPP; et al.

JAMA Health Forum

January 2023, Vol 4, No. 1
https://jamanetwork.com/journals/jama-health-forum/issue
[Reviewed earlier]

JAMA Pediatrics

January 2023, Vol 177, No. 1, Pages 3-104
https://jamanetwork.com/journals/jamapediatrics/currentissue

Original Investigation

Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults

Jun Yasuhara, MD; Kaisei Masuda, MD; Tadao Aikawa, MD, PhD; et al.

This systematic review and meta-analysis investigates the clinical features and early outcomes associated with myopericarditis after COVID-19 mRNA vaccination in a heterogeneous population of adolescents and young adults.
Review

Inclusion of Non–English-Speaking Participants in Pediatric Health Research-A Review
Annie Chen, BS; Sabrina Demaestri, BA; Kelsey Schweberger, MD; et al.

This review assesses the frequency of which non–English-speaking participants are included in pediatric research and the methodological details provided about communication with these participants.

JBI Evidence Synthesis
December 2022 - Volume 20 - Issue 12
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[New issue; No digest content identified]

Journal of Adolescent Health
February 2023 Volume 72 Issue 2 p161-314
https://www.jahonline.org/current
[New issue; No digest content identified]

Journal of Artificial Intelligence Research
Vol. 76 (2023)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 6, December 2022
https://link.springer.com/journal/10900/volumes-and-issues/47-6
[Reviewed earlier]

Journal of Development Economics
Volume 160 January 2023
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 5, December 2022
http://journals.sagepub.com/toc/jre/current
Ethical Issues using Digital Surveillance Technologies in Research
[Reviewed earlier]
Journal of Epidemiology & Community Health
December 2022 - Volume 76 - 12
https://jech.bmj.com/content/76/12
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 15, Issue 4 Pages: 315-424 December 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[New issue; No digest content identified]

Journal of Global Ethics
Volume 18, Issue 2, 2022
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 4, November 2022
https://muse.jhu.edu/issue/48371
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 25, issue 1, February 2023
Contents
Suboptimal Serologic Immunity Against Poliomyelitis Among New Migrant Children in Greece Calls for Organized Action
Authors (first, second and last of 9)
Christina Ioannidou
Petros Galanis
Ioanna D. Pavlopoulou
Content type: Original Paper
Published: 20 April 2022
Pages: 96 - 103

Journal of Immigrant & Refugee Studies
Volume 20, 2022 Issue 4
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Journal of International Development
Volume 34, Issue 8 Pages: 1453-1648 November 2022
https://onlinelibrary.wiley.com/toc/10991328/current
[Reviewed earlier]

Journal of Medical Ethics
December 2022 - Volume 48 - 12
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 9, Issue 3 (2022)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
January 2023 Volume 252 p1-226
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 07 Jan 2023]
[No new digest content identified]

Journal of Public Health Management & Practice
November/December 2022 - Volume 28 - Issue 6
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 43, issue 4, December 2022
https://link.springer.com/journal/41271/volumes-and-issues/43-4
[Reviewed earlier]

Journal of Refugee & Global Health
Editorial
Response to the multi-country monkeypox outbreak: a view from Africa
Oyewale Tomori, PhD, Lucille Blumberg, MMed, (Clin Micro)
Journal of Travel Medicine, Volume 29, Issue 8, December 2022, taac138,
https://doi.org/10.1093/jtm/taac138

COVID-19 vaccines: the imperfect instruments of vaccine diplomacy
Peter J Hotez, MD, PhD
Journal of Travel Medicine, Volume 29, Issue 8, December 2022, taac063,
https://doi.org/10.1093/jtm/taac063
Although true vaccine diplomacy in the form of sharing vaccine development technologies and scientific cooperation with low- and middle-income countries has not been a dominant theme in the COVID-19 pandemic, this aspect is now taking off and generating some exciting new possibilities.

Perspective
Refugee settlements, sewage pollution, COVID-19 and the unfolding cholera outbreak in Lebanon
Issmat I Kassem, PhD, Marwan Osman, PhD, Hadi Jaafar, PhD, Khaled El Omari, PhD
Journal of Travel Medicine, Volume 29, Issue 8, December 2022, taac142,
https://doi.org/10.1093/jtm/taac142
We have previously documented that the unsanitary conditions in the Syrian refugee settlements and pollution in Lebanon were suitable for the proliferation of infectious diseases. Here, we discuss how cholera is spreading rapidly across Lebanon, where a Syrian man from an informal settlement is thought to be the index case.

Monkeypox and ring vaccination during the FIFA world cup 2022 in Qatar: a call for action
Ramadan Abdelmoez Farahat, MBBCh, Mohammad Yasir Essar, DMD, Ziad A Memish, MD, FRCPC, FACP, FFPH
Journal of Travel Medicine, Volume 29, Issue 8, December 2022, taac103,
https://doi.org/10.1093/jtm/taac103
Given the potential spread of monkeypox (MPX) during the FIFA world cup 2022 in Qatar, appropriate precautions should be taken for early containment. Ring vaccination is an appropriate measure in this regard due to its ability not only to break the MPX transmission chain but also to prevent its progression.
**Introduction**

Before the onset of the COVID-19 pandemic, achievements in childhood vaccine coverage in the USA and globally appeared imperiled. Misinformation about vaccines was pervasive. Vaccine hesitancy—a motivational state of being conflicted about, or opposed to, vaccination—was a top ten global health threat. And vaccine-preventable diseases, such as measles, re-emerged following decades of successful control. Since the arrival of COVID-19, disruptions to childhood vaccine delivery have further jeopardised childhood vaccination efforts.

However, the effects of the pandemic on childhood vaccination have the potential to extend beyond disruptions in vaccine delivery. What will be the legacy of the COVID-19 pandemic for childhood vaccination? In this Viewpoint, we discuss how the pandemic might affect trust, risk perception, mandates, and health equity in the context of childhood vaccination. We then propose several recommendations to mitigate potential negative effects and help sustain confidence in childhood vaccines.
Editorial

Universal access to health care across the life course
The Lancet Global Health

Comment

Human papillomavirus vaccination strategies for accelerating action towards cervical cancer elimination
Anita Shet, Naor Bar-Zeev

Articles

Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis
Élodie Bénard, et al. on behalf of the HATUA Consortium

Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data
Yuanyuan Liang, et al.

Review

Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities
Sébastien Morin, et al.

Health Policy

The use of imagery in global health: an analysis of infectious disease documents and a framework to guide practice
Esmita Charani, et al.

Lancet Infectious Diseases

Jan 2023 Volume 23 Number 1 p1-130, e1-e46
https://www.thelancet.com/journals/laninf/issue/current

Editorial

Twin threats: climate change and zoonoses
The Lancet Infectious Diseases

Articles

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study
Sara Carazo, et al.
**Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study**
Megan Bardsley, et al.
Open Access

**Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study**
Ofra Amir, et al.

**Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape**
Natalie I Mazur, et al.

---

**Lancet Public Health**
Jan 2023  Volume 8  Number 1  e1-e84
https://www.thelancet.com/journals/lanpub/issue/current
[New issue; No digest content identified]

**Lancet Respiratory Medicine**
Jan 2023  Volume 11  Number 1  p1-110, e1-e11
https://www.thelancet.com/journals/lanres/issue/current

**Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis**
Elenor Jones-Gray, et al.

---

**Maternal and Child Health Journal**
Volume 26, issue 12, December 2022
https://link.springer.com/journal/10995/volumes-and-issues/26-12

**Factors Influencing Maternal Antepartum Tdap Vaccination**
Authors (first, second and last of 5)
- Henry H. Bernstein
- Stephanie Tong-Miller
- Cathie Spino
Content type: Original Paper
Published: 29 September 2022
Pages: 2385 - 2395

**Perspectives on Maternal Vaccination from Obstetrical Clinicians: A Qualitative Multi-site Study**
Authors (first, second and last of 7)
- Sharon G. Humiston
- Peter G. Szilagyi
There’s no room for COVID complacency in 2023

Stark scenes from China show the pandemic is far from over. One solution is a laser-like focus on strengthening public-health systems.

Analysis
The WHO estimates of excess mortality associated with the COVID-19 pandemic

Msemburi et al. describe how the World Health Organization has estimated the excess mortality associated with the COVID-19 pandemic, by month and for 2020 and 2021, and analyse their estimates across the WHO member states, with 14.83 million global excess deaths estimated.

William Msemburi, Ariel Karlinsky, Jon Wakefield

Analysis Open Access 14 Dec 2022
Papers and patents are becoming less disruptive over time

A decline in disruptive science and technology over time is reported, representing a substantive shift in science and technology, which is attributed in part to the reliance on a narrower set of existing knowledge.

Michael Park, Erin Leahey, Russell J. Funk

Article 04 Jan 2023

Abstract
Theories of scientific and technological change view discovery and invention as endogenous processes, wherein previous accumulated knowledge enables future progress by allowing researchers to, in Newton’s words, ‘stand on the shoulders of giants’. Recent decades have witnessed exponential growth in the volume of new scientific and technological knowledge, thereby creating conditions that should be ripe for major advances. Yet contrary to this view, studies suggest that progress is slowing in several major fields. Here, we analyse these claims at scale.
across six decades, using data on 45 million papers and 3.9 million patents from six large-scale datasets, together with a new quantitative metric—the CD index— that characterizes how papers and patents change networks of citations in science and technology. We find that papers and patents are increasingly less likely to break with the past in ways that push science and technology in new directions. This pattern holds universally across fields and is robust across multiple different citation-and text-based metrics. Subsequently, we link this decline in disruptiveness to a narrowing in the use of previous knowledge, allowing us to reconcile the patterns we observe with the ‘shoulders of giants’ view. We find that the observed declines are unlikely to be driven by changes in the quality of published science, citation practices or field-specific factors. Overall, our results suggest that slowing rates of disruption may reflect a fundamental shift in the nature of science and technology.

**Nature Biotechnology**
Volume 40 Issue 12, December 2022
https://www.nature.com/nbt/volumes/40/issues/12

**Global health equity: the next waiver**
Putting life science in the service of the global South requires reconstitution of the biotech model, not patent waivers
Editorial 07 Dec 2022

**Biopharmaceutical benchmarks 2022**
Monoclonal antibodies as a group continue to lead biopharmaceuticals in numbers of approvals and sales, although COVID-19 vaccines shot to the top of the list of highest-grossing individual products.
Gary Walsh
Eithne Walsh
Feature 05 Dec 2022

**Viral variant-resolved wastewater surveillance of SARS-CoV-2 at national scale**
Wastewater surveillance of SARS-CoV-2 at the national scale tracks emerging variants.
Fabian Amman
Rudolf Markt
Andreas Bergthaler
Article 18 Jul 2022

**Nature Communications**
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 07 Jan 2023)
[No new digest content identified]

**Nature Genetics**
Volume 54 Issue 12, December 2022
https://www.nature.com/ng/volumes/54/issues/12
[Reviewed earlier]
Eight rules to combat medical misinformation

Authors of biomedical research should provide clear and accurate information to society, whilst working to combat misinformation and disinformation.
Carl T. Bergstrom
World View 13 Dec 2022

Impact of the Human Cell Atlas on medicine

This Perspective outlines how cell atlases can provide the missing links between genes, diseases and therapies, with advances already being made in several fields, including COVID-19 and cancer.
Jennifer E. Rood, Aidan Maartens, Aviv Regev
Perspective 08 Dec 2022

Pandemic vaccines: a formidable challenge for pharmacovigilance

The COVID-19 vaccine effort was the most rapid global response to a health crisis in history. The challenge of managing unparalleled volumes of safety information provided unique opportunities to evaluate the robustness of current pharmaceutical industry pharmacovigilance practices and test novel approaches to strengthen safety signal detection, evaluation and communication.
Alexandre Kiazand, Ruth Luther, Magnus Ysander
Comment 28 Oct 2022

Nature Reviews Genetics
Volume 24 Issue 1, January 2023
https://www.nature.com/nrg/volumes/24/issues/1
[New issue; No digest content identified]

Nature Reviews Immunology
Volume 23 Issue 1, January 2023
https://www.nature.com/nri/volumes/23/issues/1
[New issue; No digest content identified]
Challenges and developments in universal vaccine design against SARS-CoV-2 variants

Fangxin Zhao, Xiaodong Zai, Wei Chen
Review Article Open Access 19 Dec 2022
Research Article
Did Massachusetts COVID-19 vaccine lottery increase vaccine uptake?
Yeunkyoung Kim, Jihye Kim, Yue Li
Research Article | published 04 Jan 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0279283

Trustworthiness of information sources on vaccines for COVID-19 prevention among Brazilians
Adriana Teixeira Reis, Karla Gonçalves Camacho, Maria de Fátima Junqueira-Marinho, Saint Clair dos Santos Gomes Junior, Dimitri Marques Abramov, Livia Almeida de Menezes, Marcio Fernandes Nehab, Carlos Eduardo da Silva Figueiredo, Maria Elisabeth Lopes Moreira, Zilton Farias Meira de Vasconcelos, Flavia Amendola Anisio de Carvalho, Livia de Rezende de Mello, Roberta Fernandes Correia, Zina Maria Almeida de Azevedo, Margarida dos Santos Salú, Daniella Campelo Batalha Cox Moore
Research Article | published 03 Jan 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0279393

An equitable vaccine delivery system: Lessons from the COVID-19 vaccine rollout in Canada
Ksenia Kholina, Shawn H. E. Harmon, Janice E. Graham
Research Article | published 30 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0279929

COVID-19 vaccine knowledge, attitudes, and experiences of health care workers in Perth, Western Australia: A qualitative study
Samantha J. Carlson, Sian Tomkinson, Christopher C. Blyth, Katie Attwell
Research Article | published 30 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0279557

Parents’ intention to vaccinate their child for COVID-19: A mixed-methods study (CoVAccS–wave 3)
Louise E. Smith, Susan M. Sherman, Julius Sim, Richard Amlôt, Megan Cutts, Hannah Dasch, Nick Sevdalis, G. James Rubin
Research Article | published 27 Dec 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0279285

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 07 Jan 2023]
[No new digest content identified]
Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 07 Jan 2023]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
30 Dec 2022
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Special report | Portuguese |

28 Dec 2022
Public health measures during the COVID-19 pandemic in institutions for the protection of children and adolescents in two departments in Colombia
Original research | Spanish |

Risk Analysis
Volume 42, Issue 10 Pages: 2125-2343 October 2022
https://onlinelibrary.wiley.com/toc/15396924/current
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 07 Jan 2023]
[No new digest content identified]

Science
Volume 379| Issue 6627| 6 Jan 2023
https://www.science.org/toc/science/current
[New issue; No digest content identified]

Science and Engineering Ethics
Volume 28, issue 6, December 2022
[Reviewed earlier]
Consolidating a research agenda for vaccine mandates
Katie Attwell, Marco Rizzi, Katharina T. Paul
Pages 7353-7359
Highlights
:: The pandemic pushed vaccine mandates to the forefront of global public health policy.
:: This special issue synthesises the findings of research in the field.
:: Scholars employ a range of methodologies to study speculative and real mandates.
:: Scholars study vaccine mandates at different stages of the policy cycle.
:: Scholars analyse mandates' impact on vaccine coverage rates and wider experiences.

Research article  Open access
Attitudes towards mandatory vaccination and sanctions for vaccination refusal
Pamela Slotte, Linda C. Karlsson, Anna Soveri
Pages 7378-7388

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 07 Jan 2023]

Latest Articles
Open Access  Article
COVID-19 Vaccine Hesitancy and Related Factors among Unvaccinated Pregnant Women during the Pandemic Period in Turkey
by Mehmet Akif Sezerol and Selin Davun
Vaccines 2023, 11(1), 132; https://doi.org/10.3390/vaccines11010132 - 05 Jan 2023

Abstract
The COVID-19 virus appeared in Wuhan, China in 2019 and spread rapidly all over the world. Vaccination guidelines have recommended pregnant women to get vaccinated against COVID-19 to prevent disease. This study aimed to understand the willingness of pregnant women to vaccinate and

Open Access  Article
COVID-19 Vaccine Hesitancy and Related Factors among Unvaccinated Pregnant Women during the Pandemic Period in Turkey
by Mehmet Akif Sezerol and Selin Davun
Vaccines 2023, 11(1), 132; https://doi.org/10.3390/vaccines11010132 - 05 Jan 2023

Abstract
The COVID-19 virus appeared in Wuhan, China in 2019 and spread rapidly all over the world. Vaccination guidelines have recommended pregnant women to get vaccinated against COVID-19 to prevent disease. This study aimed to understand the willingness of pregnant women to vaccinate and

Value in Health
December 2022 Volume 25 Issue 12 p1925-2080
https://www.valueinhealthjournal.com/current
[Reviewed earlier]
Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 06 Jan 2023]
Selected Research
[No new digest content identified]

medRxiv
https://www.medrxiv.org/content/about-medrxiv
[Accessed 06 Jan 2023]
[Filter: All articles]
Selected Research
Clinical Virology and Effect of Vaccination and Monoclonal Antibodies against SARS-CoV-2 Omicron Sub variant BF.7 (BA.5.2.1.7) : A systematic review
medRxiv 2022.12.25.22283940; doi: https://doi.org/10.1101/2022.12.25.22283940 Revision

Acceptability of decentralizing childhood tuberculosis diagnosis in low-income countries with high tuberculosis incidence: experiences and perceptions from health care workers in sub-Saharan Africa and South-East Asia
Basant Joshi, Yara Voss De Lima, Douglas Mbang Massom, Sanary Kaing, Marie-France Banga, Egerton Tamba Kamara, Sheriff Sesay, Laurence Borand, Jean-Voisin Taguebue, Raoul Moh, Celso Khosa, Guillaume Breton, Juliet Mwanga-Amumpaire, Maryline Bonnet, Eric Wobudeya, Olivier Marcy, Joanna Orne-Gliemann
medRxiv 2023.01.04.23284184; doi: https://doi.org/10.1101/2023.01.04.23284184

Challenges in estimating waning effectiveness of two doses of BNT162b2 and ChAdOx1 COVID-19 vaccines beyond six months: an OpenSAFELY cohort study using linked electronic health records
medRxiv 2023.01.04.22283762; doi: https://doi.org/10.1101/2023.01.04.22283762

The 2022 RSV surge was driven by multiple viral lineages
medRxiv 2023.01.04.23284195; doi: https://doi.org/10.1101/2023.01.04.23284195
Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach
Alexandra B Hogan, Patrick Doohan, Sean L Wu, Daniela Olivera Mesa, Jaspreet Toor, Oliver J Watson, Peter Winskill, Giovanni Charles, Gregory Barnsley, Eleanor M Riley, David S Khoury, Neil M Ferguson, Azra C Ghani
medRxiv 2023.01.03.23284131; doi: https://doi.org/10.1101/2023.01.03.23284131

Genomic assessment of invasion dynamics of SARS-CoV-2 Omicron BA.1
medRxiv 2023.01.02.23284109; doi: https://doi.org/10.1101/2023.01.02.23284109

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 06 Jan 2023]
[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]
[No new digest content identified]

Wellcome Open Research
https://wellcomeopenresearch.org/browse/articles
[Accessed 06 Jan 2023]
Selected Research
[No new digest content identified]

Think Tanks
Brookings [to 07 Jan 2023]
http://www.brookings.edu/
Latest Research [Selected] No new digest content identified.

Center for Global Development [to 07 Jan 2023]
https://www.cgdev.org/
All Research [Selected] No new digest content identified.
Chatham House  [to 07 Jan 2023]
https://www.chathamhouse.org/
Selected Analysis, Comment
Members event Livestream
**The Director’s Annual Lecture 2023**
Bronwen Maddox looks ahead to the challenges of the year and sets out Chatham House’s recommendations for change.
10 January 2023 — 6:00PM TO 7:00PM

CSIS  [to07 Jan 2023]
https://www.csis.org/
Selected Reports, Events
No new digest content identified.

Kaiser Family Foundation  [to07 Jan 2023]
https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

McKinsey Global Institute
https://www.mckinsey.com/mgi/overview
Latest Research
No new digest content identified.

ODI [Overseas Development Institute]  [to 07 Jan 2023]
Publications [Selected]
No new digest content identified.

Pew Research Center  [to 07 Jan 2023]
https://www.pewresearch.org/
Latest Publications [Selected]
No new digest content identified.

Rand  [to 07 Jan 2023]
https://www.rand.org/pubs.html
Published Research [Selected]
Journal Article
**COVID-19 Vaccination Intentions, Concerns, and Facilitators Among US Parents of Children Ages 6 Months Through 4 Years**
In this study of 2,031 adults with children aged 6 months through 4 years, half indicated they intended to get their child a COVID-19 vaccine at some point, but only one-fifth intended to do so within 3 months of the child's eligibility.

Dec 21, 2022
Aaron M. Scherer, Courtney A. Gidengil, Amber M. Gedlinske, Andrew M. Parker, Natoshia M. Askelson, Kate R. Woodworth, Christine A. Petersen, Megan Lindley

Urban Institute [to 07 Jan 2023]
https://www.urban.org/publications
New Research Publications - Selected

Research Report
Catalyzing Leadership for Equity
December 30, 2022
Results and Recommendations from a Mixed Methods Analysis of Equity-Focused Leaders and Leadership Development Programs

World Economic Forum [to 07 Jan 2023]
https://agenda.weforum.org/news/
Media
No new digest content identified.

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.
CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.